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CHAPTER 1: AN OPTIMAL UBIQUITIN PROTEASOME PATHWAY IN THE 
NERVOUS SYSTEM: THE ROLE OF DEUBIQUITINATING ENZYMES 
Published: Ristic G, Tsou W-L, Todi SV (2014). An Optimal Ubiquitin-Proteasome  
Pathway in the Nervous System: The Role of Deubiquitinating Enzymes. Frontiers in Molecular 
Neuroscience. Peer-reviewed review. DOI: 10.3389/fmol.2014.00072  
1.1 Introduction 
 The Ubiquitin Proteasome Pathway (UPP) is responsible for degrading the majority of 
proteins in eukaryotic cells. The UPP is important to all steps and processes of the nervous 
system, including cell fate specification, differentiation, migration, networking and maturation, 
and is critical in maintaining neuronal homeostasis during aging. As post-mitotic cells, neurons 
cannot disperse toxic or misfolded proteins through cell division, but must instead continuously 
rid themselves of cellular components whose accumulation could be detrimental. The importance 
of the UPP to the aging nervous system is exemplified by neurodegenerative disorders such as 
Alzheimer’s, Parkinson’s and other diseases, where pathological hallmarks are the accumulation 
and aggregation of proteins with toxic properties. 
 Degradation of proteins by the UPP is a highly selective process. In order for proteins to be 
degraded by the proteasome, they require a tag to identify them as substrates. This “tagging” task 
is accomplished through the post-translational modification of substrates with the small modifier 
protein ubiquitin (Ub). Ubiquitination involves the covalent attachment of Ub via an isopeptide 
bond to a lysine residue of target proteins through the coordinated action of a Ub activating 
enzyme (E1; two such enzymes are known in mammals), a Ub conjugating enzyme (E2; ~50-75 
in mammals) and a Ub ligase (E3; >500 in mammals) (figure 1.1).  
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 Ub can be added onto a protein as a monomer or as a poly-Ub chain. Poly-Ub can take on 
different topographies due to the presence of seven lysine residues on Ub itself, creating chains 
of different linkage types: K6, K11, K27, K29, K33, K48, and K63. Different types of chains 
signal different outcomes. In the case of UPP, K48-linked chains consisting of at least four Ub 
most commonly identify a protein as a proteasome substrate (Thrower et al., 2000; Komander 
and Rape, 2012; Heride et al., 2014). K11 chains have also been implicated in protein 
degradation during mitosis (Jin et al., 2008), although it is not clear how widely these chains are 
utilized by the UPP in other cellular processes.   
 The proteasome is able to bind both K63- and K48- linked chains in reconstituted systems 
in vitro (Kim et al., 2007; Peth et al., 2010). However, in mammalian cells there appears to be 
selectivity for K48 poly-Ub by the proteasome (Nathan et al., 2013). K63-linked poly-Ub chains 
are bound by proteins involved in the Endosomal Sorting Complex Required for Transport 
(ESCRT) pathway, which do not function directly with the proteasome. Binding of K63-linked  
 
Figure 1.1: Summary of UPP.
Through the coordinated action of E1/E2/E3, Ub is conjugated to a substrate destined for proteasomal 
degradation. Ub-binding proteins that are components of the proteasome or that associate with it 
reversibly (not depicted) bind poly-Ub on the substrate, which is subsequently deubiquitinated, unfolded 
and degraded. Poly-Ub is then processed into mono-Ub which re-enters the cycle.
 3
poly-Ub by ESCRT proteins seemingly precludes proteasomal degradation of proteins modified 
with this type chain (Nathan et al., 2013). Additional specificity in poly-Ub recognition is 
provided by a family of proteasome-associated proteins, including the Rad23 orthologues 
hHR23A and hHR23B that selectively bind K48 chains (Nathan et al., 2013).  
 The 26S proteasome is a macromolecular structure composed of a catalytic 20S subunit 
and one or two 19S regulatory subunits. Ubiquitinated substrates are recognized by and bind to 
the 19S particle. This process is accomplished in part by the integral 19S receptors S5a and 
Adrm1 (Deveraux et al., 1994; Husnjak et al., 2008). Ubiquitinated proteins that are bound by 
the 19S proteasome are deubiquitinated and unfolded. The unfolded proteins can then pass 
through the hollow, cylindrical core of the 20S particle, where they are enzymatically degraded. 
 Erroneous ubiquitination of a protein could send it to the proteasome prematurely, or could 
target it for the wrong pathway (e.g. autophagy rather than the UPP), leading to unintended 
consequences for cells. Specificity for which proteins are ubiquitinated and the type of Ub 
linkage formed rests in large part with the E2/E3 pair that performs the ubiquitination process 
(Komander and Rape, 2012; Heride et al., 2014). An additional level of control is provided by 
enzymes known as deubiquitinases (DUBs), which reverse the isopeptide bond and thus help to 
control the status of protein ubiquitination. An increasing number of reports is being published 
on the role of DUBs in nearly all cellular pathways, tissues and organs, in normal homeostasis 
and in various diseases, including disorders of the nervous system (Todi and Paulson, 2011; 
Clague et al., 2013) . 
 The nearly 95 DUBs that are encoded by the human genome are subdivided into five 
categories based on homology at the catalytic domain. The Ubiquitin C-terminal Hydrolases 
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(UCH), Ubiquitin Specific Proteases (USP), Machado-Joseph Disease Protease (MJD) and 
Otubain (OTU) Proteases are cysteine proteases, while JAB1/MPN/Mov34 Metallo-enzyme 
(JAMM) proteases are Zinc-dependent metallo-proteases (figure 1.2). DUBs maintain the 
cellular pool of mono-Ub available for conjugation by processing Ub precursors; they replenish 
mono-Ub by cleaving poly-Ub chains and recycling Ub; they can fully deubiquitinate substrates 
and reverse their outcome; or they can edit poly-Ub chains on substrates to help direct them 
toward a specific pathway (figure 1.3). Although at the most basic level all catalytically active 
DUBs perform the same function – disassembly of Ub-protein bonds – in vitro and in vivo 
studies have collected evidence that these proteases perform various non-redundant functions 
(Clague et al., 2013). Distinct roles stem in part from differences in the structure of the catalytic 
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Figure 1.2 Mammalian DUBs. 
Mammalian DUBs categorized by similarities at the protease domain. Highlighted are DUBs involved in 
the nervous system. With the exception of JAMM proteases, which are zinc-dependent metallo-
proteases, the rest are cysteine proteases.
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domains of DUBs and in part from interaction domains and subcellular localization signals 
encoded in their amino acid sequences. 
 Three DUBs associate directly with the proteasome: PSMD14, USP14 and UCHL5. 
PSMD14 is a stoichiometric component of the 19S regulatory subunit, whereas USP14 and 
UCHL5 associate transiently with it during protein degradation. Several other DUBs function in 
conjunction with the UPP at steps that precede the proteasome (e.g. during substrate 
ubiquitination) or following substrate binding to the 19S (e.g. during ubiquitin chain disassembly 
and ubiquitin recycling; figure 1.4 on page 23). The following sections provide details on UPP-
related DUBs in the nervous system, with examples from each sub-class of this family. The 
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Figure 1.3: Roles of DUBs in Ub Homeostasis.  
Diagrammatic summary of the various functions of DUBs in Ub homeostasis. Newly produced Ub is C-
terminally fused to other proteins, such as other Ub molecules, and must be cleaved by DUBs in order 
for its terminal glycine residue to be exposed for isopeptide bond formation. Once conjugated to a 
substrate protein, poly-Ub chains can be edited, or can be completely removed. Poly-Ub chains that are 
unanchored are processed into single Ub and re-enter the Ub conjugation cycle.
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exception are OTU proteases, for which there are few mechanistic data relating them to the UPP 
in the nervous system. Information that has been reported so far on OTUs is included in Table 1 
at the end of this chapter, which is a comprehensive list of DUBs implicated in the nervous 
system, and also includes proteases that do not necessarily function through the UPP.   
1.2 UPP-Related DUBs in the Nervous System 
1.2.1 Proteasome-Associated DUBs 
PSMD14 
 This metallo-protease belongs to the JAMM sub-family of DUBs. It is also known as 
POH1. PSMD14 is a constitutive subunit of the proteasome, a member of the 19S regulatory 
complex, where it neighbors the ubiquitin receptor Adrm1 (Beck et al., 2012). Its reported role is 
to deubiquitinate proteins at the proteasomes before they are degraded. By removing ubiquitin  
chains en bloc from substrates, PSMD14 plays an important role in facilitating protein 
degradation, as well as in Ub recycling. Once poly-Ub is removed from substrates by PSMD14 it 
is disassembled by other DUBs, for example USP5 (Clague et al., 2013; Liu and Jacobson, 
2013). 
 PSMD14 and its role at the proteasome were uncovered through studies in yeast that 
examined how deubiquitination and degradation of a substrate are coupled. In yeast, PSMD14 is 
known as Rpn11. Through the use of an unfolded, ubiquitinated model substrate, it was shown 
that deubiquitination occurs after a protein is bound by the proteasome. Mutating Ub so that it 
can no longer be cleaved by DUBs leads to a significant reduction of substrate degradation. 
Other studies showed the substrate deubiquitination at the proteasome is insensitive to molecules 
that block cysteine proteases, whereas a zinc chelator blocks deubiquitination, suggesting a 
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metallo-enzyme. Mutations in Rpn11 stabilize UPP substrates and are lethal in yeast. These and 
other studies pointed to Rpn11 as the DUB functioning at the proteasome, bridging substrate 
deubiquitination and degradation (Verma et al., 2002; Yao and Cohen, 2002).  
 Work conducted in mammalian cell culture implicated PSMD14 in maintaining the post-
mitotic status of neurons. RNAi-mediated knockdown of PSMD14 in mouse midbrain and 
cortical cultures leads to de novo synthesis of DNA and an increase in apoptosis (Staropoli and 
Abeliovich, 2005). The mechanism behind these observations is unclear, but the data suggest a 
critical role for UPP in preventing neurons from re-entering mitosis. Perhaps disturbance of the 
UPP (from the perspective of PSMD14) triggers a general cellular stress response that ultimately 
leads to neuronal death. Alternatively, the UPP could be involved in the continuous turnover of 
specific factors that induce mitotic re-entry. Highlighting the importance of PSMD14 to the 
nervous system, RNAi-mediated knockdown of its orthologue in neurons in Drosophila causes 
larval lethality (Tsou et al., 2012). 
 PSMD14 is one of very few DUB with a specific function, in this case, the removal of 
poly-Ub chains in a single swoop from substrates at the proteasome. As it will become clear 
through the remainder of this chapter, it is difficult to categorize most DUBs as operating in only 
one step, or acting on only one substrate, pathway, tissue or organ. Perhaps PSMD14 is an 
exception because of its continuous presence at the 19S subunit, where it is precluded from 
interacting with other potential partners. Most other DUBs do not appear to reside in a single 
constitutive molecular complex and can thus conduct different functions depending on their 
interactions. 
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UCHL5 
 This DUB is a member of the UCH sub-family and is also known as UCH37. Unlike 
PSMD14, UCHL5 is not a constitutive subunit of the proteasome but associates with it by 
binding to the Ub receptor Adrm1 on the 19S subunit (Lee et al., 2010a; Lee et al., 2010b). The 
proposed role for this DUB at the proteasome is one of poly-Ub chain trimming by hydrolyzing 
Ub chains at their distal end and releasing mono-Ub for re-utilization (Yao et al., 2006). UCHL5 
deubiquitinating activity has been shown to increase once it is bound to the proteasome (Qiu et 
al., 2006; Yao et al., 2006). Based on more recent work, UCHL5 stimulates the activity of the 
proteasome by regulating ATP hydrolysis and 20S gate opening (Peth et al., 2009; Peth et al., 
2013a; Peth et al., 2013b). 
 Studies in a Uchl5-null mouse line showed that this protease is important for brain 
development. Uchl5 knockout embryos have malformations in various brain areas, including the 
telenecephalon, mesencephalon and metencephalon (Al-Shami et al., 2010). The reasons for 
these specific anomalies are not known. Other proteasome-associated DUBs, such as USP14, 
which is discussed next and which also processes chains to yield mono-Ub, appear unable to 
compensate for the loss of UCHL5 in the brain, indicating a non-redundant role for this DUB in 
the brain. 
USP14 
 USP14 belongs to the USP sub-family of DUBs. It reversibly associates with the 19S 
proteasome, where it is responsible for trimming Ub chains on substrates that are destined for 
degradation and thus recycling mono-Ub. The catalytic activity of USP14 is enhanced by its 
binding to the proteasome several hundred-fold (Lee et al., 2010a; Lee et al., 2010b), suggesting 
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that this DUB needs the proteasome in order to conduct functions that require its protease 
activity. 
 Depletion of USP14 alone enhances proteasome activity, whereas co-depletion with 
UCHL5 inhibits the proteasome (Koulich et al., 2008), indicating some cross-dependence for 
these DUBs during protein degradation. Critical information on the function of USP14 has come 
from yeast studies, where depletion of Ub leads to an upregulation of its orthologue, Ubp6 
(Hanna et al., 2006), which restores Ub balance. Not all functions of USP14 at the proteasome 
depend on its catalytic activity: binding of USP14 to poly-Ub chains and unfolded peptides 
results in opening of the gates of the 20S proteasome and stimulation of the ATPase activity of 
the proteasome (Peth et al., 2009; Peth et al., 2013a; Peth et al., 2013b). Collectively, these 
findings implicated USP14 with keeping proteasomal activity under check. 
 A role for USP14 in the nervous system was first demonstrated by the identification of a 
recessive mutation in the Usp14 gene, which causes ataxia in the axJ mouse line. Homozygous 
axJ mice suffer from progressive motor impairment including ataxia and tremor, reduced body 
and brain mass, paralysis and death by two months of age. The axJ mutation results from the 
insertion of an intracisternal-A particle into intron 5 of Usp14, leading to ~95% lower levels of 
USP14 protein in the brain of homozygous mice (Wilson et al., 2002; Anderson et al., 2005). In 
contrast to many mouse models of neurodegenerative diseases, axJ mice do not show neuronal 
loss or abnormal protein accumulation (Wilson et al., 2002). Instead, axJ mice have reduced 
mono-Ub levels, particularly in synaptosomal fractions (Anderson et al., 2005; Chen et al., 2009; 
Chen et al., 2011). Because introduction of Ub in neurons in an axJ background largely 
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suppresses the phenotype (Chen et al., 2011), indicating that a primary role of USP14 in the 
central nervous system is Ub homeostasis. 
 USP14 is critically important at the neuromuscular junction (NMJ). Electrophysiological 
Recordings in axJ mice reveal defective release of the neurotransmitter acetylcholine (ACh) at 
the NMJ, and loss of USP14 leads to developmental anomalies at the pre- and post-synaptic 
terminals of the NMJ (Chen et al., 2009). The NMJs of axJ mice are swollen and poorly 
arborized, with aberrant nerve terminals and an immature morphology of ACh receptor clusters. 
These changes correlate with loss of mono-Ub, and are corrected by exogenous expression of Ub 
in neurons (Chen et al., 2009; Chen et al., 2011). 
The ataxia phenotype in the axJ mice suggests that the cerebellum is negatively affected 
by nearly absent USP14. A potential role for this DUB in regulating the activity of cerebellar 
Purkinje Cells has been reported. In axJ mice, Purkinje Cells have increased cell surface 
expression of GABAAReceptors (GABAAR) in extrasynaptic regions, with a concomitant 
increase in inhibitory GABAergic currents that effectively reduces cerebellar output (Lappe-
Siefke et al., 2009). GABAAR is ubiquitinated in cells and USP14, which interacts directly with 
this receptor, may deubiquitinate it (Lappe-Siefke et al., 2009). Generally speaking, mono-
ubiquitination controls recycling of various receptors to and from the cell membrane, including 
GABAAR (Saliba et al., 2007). Consequently, USP14 deficiency may cause ataxia in the axJ 
mice in part by perturbing the turnover and/or cell surface distribution of GABAAR. Still, since it 
is not clear that USP14 directly deubiquitinates GABAAR, it is also worth considering that this 
DUB may regulate the receptor indirectly. After all, USP14 is a sluggish protease outside of the 
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proteasomal context, leading one to wonder whether it can deubiquitinate GABAAR in the 
absence of factors that enhances its catalytic activity. 
Because of the early lethality phenotype in the axJ mice, it has been difficult to 
investigate whether USP14 is important in adults. Recently, another mutation in Usp14 was 
identified (Marshall et al., 2013). This mutation, nmf375, leads to ~95% reduction in USP14 
protein levels when homozygous, similar to the reduction observed in axJ mice. However, unlike 
axJ homozygous mice, ones carrying two copies of nmf375 do not present with phenotypes early 
in life. Deterioration of motor performance is observed around 12 months of age (axJ mice die by 
2 months) and is associated with mono-Ub depletion (Marshall et al., 2013). These data indicate 
that USP14 plays an important role not only for NMJ development, but also for its maintenance. 
They also highlight the importance of genetic modifiers; mutations that lead to similar reduction 
in USP14 protein levels in different genetic backgrounds have markedly different phenotypic 
onset and progression. Placing the nmf375 into the same genetic background as the axJ leads to a 
dramatically earlier phenotype, even more severe than axJ (Marshall et al., 2013). Perhaps future 
genetic analyses will identify factors that modulate the phenotype caused by this UPP-related 
DUB. Could these modifiers be other DUBs related to the UPP, or are they E3 ligases that 
counteract USP14 function? 
Studies from yeast, mammalian cell culture and mice together indicate that USP14 plays 
an important role in recycling mono-Ub by functioning at the proteasome. Other studies have 
presented the possibility that this DUB has specific substrates, potentially outside of the UPP. As 
described later, there is even evidence from cell culture that USP14 prevents the degradation of 
some ubiquitinated substrates at the proteasome, adding further complexity to the functions of 
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this protease (see the section on “The use of DUBs for therapeutic purposes”). Future work may 
find distinct binding partners of USP14 that depend on cell type, the state of neuronal activity, 
and on sub-cellular localization. In turn, these partners may dictate the precise function of USP14 
as a DUB, or even as a scaffolding protein. 
1.2.2 DUBs that function in conjunction with the UPP 
UCHL1  
 The first reported DUB with a neuronal function, UCHL1 is a member of the UCH sub-
family of DUBs. The catalytic area of UCHL1 has a loop positioned over the active site that 
limits the size of Ub adducts that can be processed by it to small peptides (Johnston et al., 1999; 
Das et al., 2006). Based on in vitro biochemical reactions, structural data and observations from 
animal studies, UCHL1 is proposed to function largely by maintaining a stable pool of mono-Ub 
for use in ubiquitination reactions (Clague et al., 2013). Newly translated Ub contains amino 
acids following the terminal glycine residue that is used for isopeptide bond formation. UCHL1 
can cleave off these additional amino acids in order to expose the final glycine of Ub for 
conjugation. UCHL1 can also help maintain mono-Ub by reversing accidental modifications that 
can form during Ub activation (Larsen et al., 1998).  
 UCHL1 was first described in Aplysia, where its orthologue is known as Ap-UCH (Hegde 
et al., 1997). This protease was found to have a role in synaptic plasticity because it was one of 
the genes that was markedly upregulated in sensory neurons following LTF (long-term 
facilitation) and LTD (long-term depression). Inhibition of Ap-UCH induction or blockage of its 
function inhibits synaptic plasticity (Chain et al., 1995; Hegde et al., 1997; Fioravante et al., 
2008). 
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 UCHL1 is among the most abundant proteins in the brain, by some estimates reaching 
1-2% (Jackson and Thompson, 1981; Doran et al., 1983; Wilkinson et al., 1992). Similar to Ap-
UCH in Aplysia, mammalian UCHL1 is linked to synaptic function. Studies of mouse knockouts 
of the Uchl1 gene indicate that this DUB is important for the structure and function of the NMJ. 
Uchl1 knockout mice develop normally, but die prematurely after a period of spasticity and 
paralysis. At the level of the NMJ, Uchl1 knockouts show a significant decrease in the release of 
ACh from the synaptic terminal (Chen et al., 2010), which could be due to perturbed Ub-
dependent pathways as a result of decreased Ub recycling. This reduction in content release is 
accompanied by hindered synaptic plasticity, nerve terminal retraction and axonal degeneration 
(Chen et al., 2010). Supportive evidence for a role for UCHL1 at the synapse also comes from 
the gad (gracile axonal dystrophy) mouse line, which has an intragenic Uchl1 deletion (Saigoh et 
al., 1999). Similar to the Uchl1 knockout mice, ones homozygous for gad present with a dying-
back type of axonal degeneration. Lastly, studies in rat hippocampal slices also collected 
evidence that UCHL1 is important for synaptic plasticity by maintaining mono-Ub. Increased 
UCHL1 activity leads to higher levels of mono-Ub, whereas pharmacological inhibition of this 
DUB had the opposite effect and is associated with anomalous synaptic spine structure (Cartier 
et al., 2009). Importantly, anomalies at the synaptic level during UCHL1 inhibition are rescued 
by the introduction of mono-Ub (Cartier et al., 2009). Together, these data indicate that a primary 
role for UCHL1 in the nervous system is to maintain mono-Ub available for utilization during 
inter-cellular communication. This pool of mono-Ub could be utilized by the UPP as well as 
other types of cellular pathways and processes, such as gene transcription, receptor 
internalization, autophagy, etc.  
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 UCHL1 is important to the aging nervous system, as highlighted by the connection of this 
DUB to age-related diseases, including Alzheimer's (AD) and Parkinson’s (PD). Based on 
proteomic studies, UCHL1 is a major target of oxidative damage in AD and PD post-mortem 
human brains (Choi et al., 2004). UCHL1 protein levels are reduced in the hippocampus of a 
transgenic mouse model of AD that has learning deficits and impaired LTF (Gong et al., 2006). 
Similarly, soluble UCHL1 levels are decreased in post-mortem AD brains, potentially due to its 
sequestration in neurofibrillary tangles (Setsuie and Wada, 2007). Introduction of UCHL1 in 
transgenic AD mice and in cultured cells alleviates cognitive defects and restores synaptic 
plasticity in a manner dependent on its catalytic activity (Gong et al., 2006). These and other 
findings support previously mentioned data that UCHL1 is important at synapses, and suggest 
that increased UCHL1 activity could counteract certain symptoms in AD.  
  Other work proposes that UCHL1 has specific substrates and may increase UPP-
dependent degradation of the β-site amyloid precursor protein (APP) cleaving enzyme 1 
(BACE1). BACE1 sequentially cleaves APP into amyloid ß (Aß) protein, which is a major 
component of neuritic plaques, a hallmark of AD. Pharmacological inhibition of UCHL1 in 
cultured cells leads to an increase in BACE1 protein levels, whereas an increase in UCHL1 
levels has the opposite effect and is associated with reduced levels of Aß protein. Studies in 
cultured cells are supported by investigations in gad mice. Measuring hippocampal levels of 
BACE1 by western blotting shows an increase in its protein levels in gad mice compared to wild 
type counterparts (Zhang et al., 2012). Whether UCHL1, with its physically constrained catalytic 
site, can deubiquitinate BACE1 and how this would accelerate its degradation is presently 
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unclear. Another possibility is that reduced mono-Ub levels as a result of UCHL1 perturbation 
inhibits the UPP more generally, which in turn impacts BACE1 stability. 
In relation to PD, a missense mutation in UCHL1 (I93M) was described in 1998 as the 
cause of dominantly-inherited PD in a family (Leroy et al., 1998). In in vitro reconstituted 
assays, UCHL1I93M was found to have reduced DUB activity (Nishikawa et al., 2003), thus it 
was initially hypothesized that PD could be due to partial loss of UCHL1 activity. However, 
mice lacking UCHL1 do not develop neurodegenerative hallmarks of PD, such as loss of 
dopaminergic neurons, indicating that PD in the I93M family might not be due to reduced 
UCHL1 activity, but could result from a gain-of-function. To examine this latter possibility, 
transgenic mice were generated expressing UCHL1I93M. These mice show loss of nigral 
dopaminergic neurons, as is characteristically seen in PD, and develop Ub- and UCHL1-positive 
inclusions, although not Lewy Bodies, which are the histopathological hallmark of PD (Setsuie 
and Wada, 2007; Setsuie et al., 2007; Tan and Skipper, 2007). According to these results, 
UCHL1I93M could cause neurodegeneration through a gain-of-function mechanism. The 
molecular process through which this mutation would impact UCHL1 cellular function, 
localization or other properties is unclear. 
 Another report that linked UCHL1 to PD presented evidence that the DUB activity of a 
farnesylated, membrane-bound form of this protease rescues the PD protein, α-synuclein, from 
lysosomal degradation (Liu et al., 2009). α-synuclein is implicated in the buildup of aggregated 
structures in patient brains, and this buildup is believed to be one cause of death of dopaminergic 
neurons in PD (Kruger et al., 1998; Athanassiadou et al., 1999; Tan and Skipper, 2007). If it is 
confirmed in vivo that farnesylated UCHL1 has a significant role in the turnover of α-synuclein, 
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it would suggest this DUB as a potential therapeutic target for PD. Severing UCHL1 from the 
membrane might increase the degradation of α-synuclein, effectively reducing levels of this 
aggregation-prone protein and alleviating neuronal stress. As it will be discussed later, α-
synuclein can be degraded by the proteasome as well as through autophagy. Each type of 
degradation rests on ubiquitin-dependent processes that are controlled by DUBs such as UCHL1 
and USP9X (see below). Consequently, targeting the stability of this disease-linked protein for 
therapy will require the consideration of various regulatory processes. 
 Lastly, in 2013 three siblings from a Turkish family were discovered with a recessive, 
missense mutation in the Ub-binding domain of UCHL1 (mutation E7A), which leads to 
markedly reduced catalytic activity of this DUB in vitro. Patients from this family show early 
onset progressive neurodegenerative syndrome that includes cerebellar ataxia, spasticity, 
blindness and nystagmus (Bilguvar et al., 2013). These symptoms are different from those of PD 
patients, including the ones who carry the I93M mutation. Such phenotypic variability could be 
due to different effects of the E7A and I93M mutations on the activity and interactions of 
UCHL1, and might be compounded by other genetic differences between the families. 
 As we near the end of this section, it is important to note that mutations in two different 
DUBs, USP14 and UCHL1, which function at least by maintaining mono-Ub, cause problems at 
the NMJ and neurological defects in mice. Does this mean that they share duties at the 
molecular, cellular and tissue level? These DUBs are linked through mono-Ub: Uchl1 
transcription is upregulated in axJ mice and, vice versa, Usp14 transcription is increased in 
Uchl1-deficient mice (Walters et al., 2008), suggesting a molecular circuitry that controls the 
expression of these genes in response to depleted mono-Ub. However, this upregulation at the 
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transcription level does not lead to suppression of the phenotype, or restitution of mono-Ub 
levels. Neurological symptoms differ among Uchl1- and Usp14-deficient mice, which could be 
due to differences in genetic background. As discussed above, genetic background can have a 
profound effect on symptoms and progression of ataxia in Usp14-mutant mice (Marshall et al., 
2013). Another reason why mutations in USP14 and UCHL1 lead to different phenotypes could 
stem from partially non-redundant functions. Perhaps there are specific cellular processes (or 
substrates), populations of neurons (or glia), or stages of development for which one DUB is 
more critical than the other. While USP14 and UCHL1 have similar effects on the levels of 
mono-Ub available in neurons, they likely also play divergent roles in other aspects of neuronal 
homeostasis that remain to be elucidated. 
USP7 
 A member of the USP sub-family of DUBs, USP7 is also known as HAUSP. It has gained 
attention because it is viewed as a potential therapeutic target for malignancies. Based on 
numerous studies, USP7 functions closely with the UPP, where it opposes the proteasomal 
degradation of various substrates, including the E3 Ub ligase murine double mutant 2 (mdm2) 
and its substrate, p53, a tumor suppressor that causes cell cycle arrest and apoptosis (Clague et 
al., 2013). USP7 deubiquitinates both mdm2 (which enhances p53 degradation) and p53 (which 
inhibits p53 degradation) (Li et al., 2002; Li et al., 2004). It is the interplay of p53 and USP7 that 
may be critical for the nervous system. Through a brain-restricted knockout strategy for Usp7 in 
mice, it was shown that this DUB is essential: mice lacking USP7 in the brain die soon after birth 
and have anomalous brain development, attributed in part to p53 protein stabilization as a result 
of increased mdm2 turnover in the absence of USP7 (Kon et al., 2011). p53-independent 
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mechanisms may also be involved in neonatal lethality, because inactivation of p53 through a 
knockout strategy fails to fully rescue lethality in the absence of USP7 (Kon et al., 2011).  
 Another potential role for USP7 in the nervous system is the regulation of the repressor 
element 1-silencing transcription factor (REST), which inhibits neural cell differentiation. 
Knockdown of USP7 in neuronal progenitor cells leads to a decrease in the levels of REST 
protein. USP7 and REST co-immunoprecipitate, and USP7 knockdown results in higher levels of 
poly-Ub REST, suggesting that USP7 controls REST by deubiquitinating it (Huang et al., 2011). 
During differentiation, REST is targeted for proteasomal degradation by multiple E3 ligases. The 
levels of one such ligase, ß-TrCP, increase during neuronal differentiation, when levels of USP7 
and REST are lower. When both USP7 and ß-TrCP are knocked down, an intermediate level of 
ubiquitinated REST is observed compared to its levels in cells where only one protein is targeted 
(Huang et al., 2011). According to these results, ß-TrCP and USP7 appear to counterbalance each 
other in regulating the stability of REST. This interaction between USP7 and ß-TrCP is 
reminiscent of the USP7/mdm2 exchange with respect to p53. It is presently unclear whether 
p53-independent anomalies in brain development as a result of Usp7 knockout are due to 
perturbation in REST signaling. Collectively, these studies suggest at least two major pathways 
that can be regulated by USP7 in the nervous system: neuronal differentiation and cell viability. 
 USP7 may also regulate other processes in the brain, including in some 
neurodegenerative diseases. USP7 interacts with the gene transcription protein ataxin-1 (Hong et 
al., 2002), mutations in which cause the age-related neurodegenerative disease Spinocerebellar 
Ataxia Type 1 (Williams and Paulson, 2008). The physiological implications of this interaction 
are uncertain, but suggest the possibility of USP7 roles in stages following nervous system 
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development. Lastly, recent studies indicated that the above-mentioned transcription factor, 
REST, is positively involved in normal aging, and its loss may be implicated in AD and mild 
cognitive impairment (Lu et al., 2014). Considering the role of USP7 in REST turnover during 
development, one can extrapolate that this DUB may be neuroprotective in the aging brain by 
suppressing REST degradation. 
USP9X 
 Another member of the USP sub-family of DUBs implicated in the nervous system is 
USP9X. The Drosophila orthologue of USP9X, Faf, has been linked to the development of fly 
eyes and at the NMJ (Fischer-Vize et al., 1992; DiAntonio et al., 2001). Faf overexpression in 
Drosophila results in NMJ overgrowth, including an increase in synaptic span and the number of 
synaptic boutons. Faf genetically interacts with the E3 ligase Highwire (Hiw), because loss of 
function in Hiw results in a phenotype similar to Faf overexpression (DiAntonio et al., 2001). 
These findings implicate yet another E3 ligase/DUB pair balancing each other’s functions, 
although the molecular events downstream of Faf and Hiw remain to be uncovered. 
 In fly eyes, Faf prevents over-neuralization during development. Fruit flies lacking this 
DUB or expressing a version that is catalytically inactive have supernumerary photoreceptors 
due to aberrant differentiation of cells that normally acquire non-neural fates (Fischer-Vize et al., 
1992; Huang et al., 1995). The fate of these cells is specified through Notch-Delta signaling. Faf 
genetically interacts with Liquid facets (Lqf), an orthologue of mammalian epsins involved in 
endocytosis (Cadavid et al., 2000; Chen et al., 2002). Lqf is important for Delta internalization 
during Notch signaling and thus is a critical component of cell fate specification. In Drosophila, 
decreasing Lqf levels enhances the supernumerary photoreceptor phenotype of Faf mutants, 
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while increasing Lqf levels renders Faf unnecessary (Cadavid et al., 2000; Chen et al., 2002). 
Ubiquitination of Lqf is stabilized in Faf-less eyes, Faf and Lqf co-immunoprecipitate, and Lqf 
protein levels are lower in Faf-null mutants (Chen et al., 2002). These findings lead to the 
conclusion that Faf regulates the ubiquitination status and stability of Lqf: in the absence of Faf, 
ubiquitinated Lqf could be targeted for proteasomal degradation. It is possible that Lqf 
ubiquitination also modulates its activity. The ability of human epsins to interact with partners 
can be regulated by mono-ubiquitination (Nijman et al., 2005; Yi and Ehlers, 2007). 
Consequently, Faf-dependent deubiquitination of Lqf may control both its function and stability. 
The human version of Faf, USP9X, also interacts with the Lqf orthologue, epsin-1, and co-
localizes with it at the synapse (Chen et al., 2003). Since RNAi against USP9X stabilizes 
ubiquitinated epsin-1 in cultured cells (Chen et al., 2003), we can infer an evolutionarily 
conserved role for USP9X in regulating epsin-1 through deubiquitination.  
 USP9X has been implicated in two neurodegenerative disorders: PD and Diffuse Lewy 
Body Disease (DLBD). USP9X expression is altered in a mouse model of PD (Zhang et al., 
2010), and a portion of USP9X localizes to Lewy Bodies in PD and DLBD (Rott et al., 2011). 
Supporting the possibility of a role for USP9X in disease, studies have linked this DUB to the 
stability of α-synuclein, which has been implicated in the etiology of both PD and DLBD. 
USP9X is reported to regulate the cellular turnover of α-synuclein by deubiquitinating it. RNAi 
targeting USP9X leads to higher levels of mono-ubiquitinated α-synuclein in cultured cells and 
these two proteins co-immunoprecipitate from cultured cells and rat brain lysates. Higher levels 
of mono-ubiquitinated α-synuclein are not well tolerated by cells (Rott et al., 2011), indicating 
that USP9X activity can protect against toxicity from this protein. By deubiquitinating α-
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synuclein, USP9X seems to specify the degradative pathway through which this disease protein 
is disposed: UPP or autophagy. Unlike other proteins, α-synuclein reportedly only requires 
mono-ubiquitination to be degraded by the proteasome. However, upon deubiquitination by 
USP9X, α-synuclein is removed through autophagy (Rott et al., 2011). Perhaps this information 
on USP9X and α-synuclein can be used for therapeutics for PD and DLBD. Activators of USP9X 
are expected to reduce levels of mono-ubiquitinated α-synuclein—which is toxic to cells—and to 
increase its degradation through autophagy, resulting in a neuroprotective effect.  
As mentioned above, membrane-bound, farnesylated UCHL1 can also regulate α-
synuclein in cell culture by protecting it from lysosomal degradation through a mechanism that 
remains to be elucidated (Liu et al., 2009). It is tempting to speculate that UCHL1 prevents the 
lysosomal degradation of α-synuclein by directly deubiquitinating it, but this model would not 
necessarily fit with the data summarized above on USP9X and the degradation of this disease 
protein. Potentially, UCHL1 regulates α-synuclein indirectly by controlling other proteins that 
dictate its turnover, including perhaps USP9X. Ultimately, therapeutic approaches based on the 
role of USP9X or UCHL1 on α-synuclein need to consider how these DUBs might affect each 
other’s regulatory effect on this aggregation-prone protein. 
Ataxin-3 
 Ataxin-3 is a member of the MJD sub-family of DUBs. It first received attention because 
it is the disease protein in the neurodegenerative disorder Spinocerebellar Ataxia Type-3 (SCA3), 
also known as Machado-Joseph Disease. SCA3 is an age-related disease that belongs to the 
family of triplet repeat disorders, more specifically the polyglutamine repeat-related diseases that 
include Huntington's, Spinobulbar Muscular Atrophy, Dentatorubral-Pallidoluysian Atrophy and 
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five more SCAs (SCA1, 2, 6, 7 and 17) (Todi et al., 2007). SCA3, which is believed to be the 
most common dominantly inherited ataxia in the world, is a progressive ataxia accompanied by 
dystonia, dysarthria, spasticity, rigidity, ophthalmoparesis, dysphagia and neuropathy. Pathology 
includes degeneration of cerebellar pathways and nuclei, pontine and dentate nuclei, substantia 
nigra, globus pallidus, cranial motor nerve nuclei and anterior horn cells. SCA3 is caused by a 
CAG repeat expansion in the gene ATXN3, which encodes the DUB ataxin-3 (Costa Mdo and 
Paulson, 2012). 
 Based on in vitro biochemistry, cell-based studies and in vivo work in mice, C. elegans 
and Drosophila, ataxin-3 seems to function in the UPP (Matos et al., 2011; Costa Mdo and 
Paulson, 2012). Under some circumstances, ataxin-3 may enhance the degradation of some 
proteasome substrates (e.g. in ER-Associated Degradation (Wang et al., 2006) and in relation 
with the ubiquitin ligase CHIP (Scaglione et al., 2011)), while under other conditions it may 
decelerate proteasomal degradation of other proteins (Zhong and Pittman, 2006). Since ataxin-3 
interacts with several E3 ubiquitin ligases (CHIP, E4B, Hrd1, Parkin) and with the proteasome-
associated proteins hHR23A, hHR23B and VCP/p97 (Costa Mdo and Paulson, 2012), this DUB 
may regulate the fate of numerous UPP substrates. The precise outcome of ataxin-3 function—
increased or decreased stability of proteins—most likely depends on the protein partners with 
which it interacts.  
 Through a series of biochemical assays, it was shown that the E3 Ub ligase CHIP and its 
E2 partner Ubch5C attach long poly-Ub chains onto model substrates. Ataxin-3 cooperates with 
CHIP/Ubch5C to restrict or edit the length of these poly-Ub species. This collaboration serves to 
enhance, rather than prevent, proteasomal degradation of CHIP substrates such as iNOS 
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(Scaglione et al., 2011), probably because very long poly-Ub can hinder proteasomal activity 
(Kim et al., 2007; Kim et al., 2009). Thus, in contrast to what was described above for USP7 and 
mdm2, which can oppose each other’s activities, ataxin-3 and CHIP appear to work together to 
enhance the turnover of at least some proteins. Such collaborative interactions between ligases 
and DUBs could be common, because a proteomic study of DUBs identified numerous E3 Ub 
ligases co-precipitating with these proteases (Sowa et al., 2009). 
 There is also evidence that ataxin-3 can suppress the degradation of some UPP substrates 
in cells. Work conducted on ER-Associated Degradation indicates that this DUB deubiquitinates 
some misfolded proteins synthesized in the ER, thus preventing their proteasomal degradation. 
Ataxin-3 appears to perform this function in relation with the proteasome-associated protein 
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Figure 1.4: Summary of DUBs involved in various steps of the UPP.  
Summary of the different steps of substrate ubiquitination and degradation during which specific DUBs 
involved in the UPP are reported to function. UCHL1 maintains a pool of mono-Ub for conjugation by 
removing additional amino acids present in newly translated Ub, or by processing accidental thiol or 
amine modifications formed during Ub reactions. Once a substrate has been ubiquitinated, DUBs such 
as USP7, USP9X and, under some circumstances, ataxin-3 can deubiquitinate and rescue it from 
proteasomal degradation. Ataxin-3 has also been reported to enhance the degradation of a few 
substrates by editing poly-Ub chains for better recognition by and access to the proteasome. Once at 
the proteasome, premature deubiquitination of substrates by USP14 can prevent degradation. If a 
proteasome-bound substrate has been committed to degradation and is being unfolded, 
deubiquitination by PSMD14, UCHL5 and USP14 recycles Ub.
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VCP/p97 (Zhong and Pittman, 2006), although it has not been ruled out that ataxin-3 may also 
directly oppose the function of ER ligases such as Hrd1 or AMFR.  
 Three different knockout mouse lines for atxn3 are viable and appear to live normal lives, 
indicating that atxn3 is a non-essential gene (Schmitt et al., 2007; Reina et al., 2010; Switonski et 
al., 2011). However, this DUB might be required under certain physiological conditions. For 
example, mouse embryonic fibroblasts that lack ataxin-3 fair poorly during heat shock (Reina et 
al., 2010; Reina et al., 2012). Also, exogenous ataxin-3 suppresses toxicity from polyQ proteins 
in Drosophila (Warrick et al., 2005; Tsou et al., 2013). Whether ataxin-3 has a protective role in 
vivo in mice is less clear. In one study, evidence was presented that wild type ataxin-3 suppresses 
pathology from its disease-causing version in mouse models of SCA3 (Cemal et al., 2002). But, 
in a recent publication lack of ataxin-3 did not seem to enhance pathology in an HD mouse 
model (Zeng et al., 2013). As this latter study did not test whether higher levels of ataxin-3 had a 
protective effect, or whether catalytically inactive ataxin-3 worsened the HD phenotype, it 
remains to be clarified whether this DUB has a neuroprotective effect in mammals.  
  The molecular mechanisms that lead to polyglutamine-mediated neurodegeneration in 
SCA3 are uncertain. Based on in vitro studies, K48- and K63-linked poly-Ub binding and 
cleaving capabilities of ataxin-3 are not affected by expansions in the polyglutamine repeat 
(Burnett et al., 2003; Winborn et al., 2008; Todi et al., 2009), although its ability to cleave K27- 
and K29-linked poly-Ub is enhanced in the disease-causing version (Durcan et al., 2011). In 
cells, polyglutamine-expanded ataxin-3 is less efficient at reducing levels of ubiquitinated 
species, suggesting that some of its cellular roles are affected by expansion (Winborn et al., 
2008). Supporting the notion that polyglutamine expansion alters ataxin-3 function, a disease-
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causing version of this protease targets the E3 ubiquitin ligase parkin for degradation through 
autophagy, unlike wild type ataxin-3 (Durcan et al., 2011). Based on studies from other 
polyglutamine proteins such as ataxin-1 (Lam et al., 2006), polyglutamine repeat expansion may 
lead to both a partial loss-of- and a toxic gain-of-function for ataxin-3, although this remains to 
be elucidated. Since ataxin-3 appears to be non-essential in mice, perhaps one effective 
therapeutic route for SCA3 is to get rid of the protein, potentially without the need to 
discriminate between normal and pathogenic forms. 
1.3 The use of DUBs for therapeutic purposes  
 The UPP has attracted particular attention from a therapeutic point of view because of its 
critical role in protein quality control and, consequently, in regulating numerous cellular 
pathways. Different components of the UPP have been targeted for therapy, most commonly the 
proteasome itself, although not directly for neurological diseases.  Therapies focusing on the 
proteasome have been developed and have shown promise in the clinic. Bortezomib (PS-341/
Velcade®), which inhibits the activity of the 20S component, is a treatment option for multiple 
myeloma and mantle cell lymphoma (Clague et al., 2013). Another inhibitor, carfilzomib 
(PR-171/Kyprolis®), was generated to treat patients desensitized to bortezomib. Although both 
of these inhibitors show preference for killing cancer cells, inhibiting the proteasome itself is 
largely nonspecific and leads to various undesirable side effects (Colland, 2010; Mujtaba and 
Dou, 2011). Focusing on more specific steps and components upstream of the proteasome could 
provide desired therapeutic effects without perturbing general proteostasis. This is where DUBs 
might be particularly useful. Structural work has revealed significant differences in the catalytic 
areas of DUBs (Clague et al., 2013) that could be utilized to design DUB-specific inhibitors. 
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High-throughput screens have identified small molecule inhibitors for USP7 and UCHL1 
(Colland, 2010; Todi and Das, 2012), although the efficacy and overall effect of these inhibitors 
in intact animals, particularly in the nervous system, is not clear.  
 One DUB that has been targeted therapeutically for the nervous system is USP14. As 
discussed earlier, this DUB associates reversibly with the proteasome and is proposed to be 
important in maintaining a pool of mono-Ub for utilization. USP14 may also function by 
rescuing certain proteins destined for degradation by deubiquitinating them at the proteasome. 
Cells that do not express USP14 have enhanced clearance of several disease-related proteins, 
including tau (related to AD), TDP-43 (AD and Amyotrophic Lateral Sclerosis) and ataxin-3 
(SCA3, discussed above) (Lee et al., 2010a). This finding suggests that inhibiting the catalytic 
activity of USP14 may have therapeutic benefits. It is not clear what cellular conditions or 
substrate particularities dictate the ability of USP14 to rescue some substrates from degradation.  
 A screen was conducted to identify inhibitors of USP14, and one particularly promising 
compound was isolated, 1-[1-(4-fluorophenyl)-2,5-dimethylpropyl-3-yl]-2-pyrrolidin-1-
ylethanone (abbreviated as IU1), with remarkable specificity against the catalytic activity of 
USP14 (Lee et al., 2010a). Treatment with IU1 enhances the clearance of disease-linked proteins 
in cultured cells in a manner that is proteasome dependent (Lee et al., 2010a). A series of in vitro 
and cell-based experiments indicated that trimming of poly-Ub chains by USP14 has an 
antagonistic effect on protein degradation by the proteasome: proteasomes incubated with USP14 
show decreased degradation of a model ubiquitinated substrate compared to inactive USP14, 
which does not inhibit proteasomal degradation (Lee et al., 2010a). By inhibiting the 
deubiquitinating activity of USP14, IU1 would presumably prevent the rescue of some 
 27
ubiquitinated neurotoxic proteins at the proteasome (such as tau and ataxin-3), leading to their 
degradation. It remains to be determined if IU1 can prevent neurodegeneration in vivo, 
particularly in light of more recent work, which found that overall levels of ataxin-3 and tau were 
not different in USP14-deficient mice (Jin et al., 2012). These potential discrepancies in findings 
from cultured cells and intact animals could result from different handling of ataxin-3 and tau in 
vitro vs. in vivo.  Potentially, acute inactivation of USP14 can increase the degradation of some 
disease proteins by the proteasome without perturbing Ub homeostasis, whereas chronic 
inactivation can cause an overall disturbance in mono-Ub availability that leads to compensatory 
mechanisms of protein turnover (such as lysosomal-dependent degradation). Additonally, 
inactivation or depletion of USP14 may not have beneficial effects in all neurodegenerative 
diseases. USP14 can reduce aggregates formed by mutant huntingtin (which causes Huntington’s 
Disease) and can suppress cellular degeneration caused by this protein (Hyrskyluoto et al., 2014). 
The molecular mechanism through which USP14 has this neuroprotective effect in cells is not 
known, but it might involve: 1) mono-Ub availability for proper UPP function, 2) the 
deubiqutination of huntingtin aggregates, which are heavily ubiquitinated, for better recognition, 
access and degradation by the proteasome, as well as 3) changes in Endoplasmic Reticulum-
Associated Degradation (Hyrskyluoto et al., 2014). Altogether, these findings stress the 
importance of a deep understanding of the UPP before targeting specific components for blanket 
therapeutics in neurodegenerative diseases.  
 Other studies have hinted at potential molecules that could be used to regulate DUB 
activities in the nervous system. A recent report that investigated the mechanism through which 
metal complexes inhibit proteasome function for cancer therapy found that copper pyrithione 
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(CuPT) acts at two distinct steps: 1) by inhibiting the activity of the 20S component, and 2) by 
inhibiting USP14 and UCHL5 (Liu et al., 2014). CuPT might be a promising cancer therapeutic 
by inhibiting UPP and causing cellular death in malignant cells, although its utility in 
neurodegenerative diseases is doubtful. Inhibiting neuronal UPP would be detrimental to the 
nervous system and would exacerbate pathology. Still, CuPT might be an important experimental 
reagent to understand the function of USP14 and UCHL5 in the nervous system, especially if this 
complex can be modified so that its inhibitory roles on the 20S and USP14 and UCHL5 are 
dissociated. A molecule with such properties in fact exists: b-AP15, which inhibits the DUB 
activity of USP14 and UCHL5 (D'Arcy et al., 2011). To the best of our knowledge, neither 
compound has reportedly been utilized to investigate the nervous system. 
1.4 Conclusions 
 Understanding the functions of enzymes important for the removal of Ub from substrates 
targeted for UPP-dependent degradation provides a deeper appreciation of a basic cellular 
process essential to all eukaryotic cells. We hope to have made a convincing case that DUBs that 
function in conjunction with the UPP play critical roles in nervous system development, function 
and disease. 
 The job of the UPP is to identify proteins that need to be degraded and selectively send 
them to be destroyed by the proteasome through the utilization of an identifier, in this case, 
ubiquitination. DUBs are among the various checkpoints that ensure the ubiquitination of correct 
substrates.  Some such proteases, like ataxin-3, can function by editing the type of chain attached 
to a substrate in order to enhance the proteasomal degradation of a specific protein. Others, 
exemplified by USP7 and USP9X, can oppose the function of specific E3 Ub ligases, leading to 
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the stabilization of some proteasomal substrates. DUBs such as UCHL1, UCHL5 and PSMD14 
seem critical for mono-Ub homeostasis; others, like USP14, control the UPP through multiple, 
seemingly contradictory, activities: by recycling Ub for reuse, by increasing proteasome 
function, and sometimes by rescuing specific substrates from degradation (figure 1.4).  
 As there are nearly 95 genes encoding DUBs in humans, one would think that there would 
be redundancy built into the functions of this family of proteases. However, studies in various 
animal models indicate that redundancy is not common among DUBs (Clague et al., 2013). 
Mutations or knockouts of different DUBs lead to distinct developmental anomalies or 
neurological disorders, supporting the idea that while some DUBs share duties, they also have 
roles in pathways, cells, tissues, organs and stages of development that cannot be fully 
compensated by other members of their family. 
  While we have learned a tremendous amount about the UPP and the role of DUBs in it, 
much remains to be uncovered, particularly in relation to the nervous system. Each time a door is 
opened by new research, a spiraling corridor is revealed with more possibilities to consider and 
opportunities to explore. Details on UPP-related DUBs in specific neuronal circuits are limited. 
We lack an expression and localization atlas of DUBs during development and in adults, during 
increased periods of activity and in resting times, in different areas of the brain and spinal cord, 
in different types of neuronal and glial cells and in distinct sub-cellular compartments. Such 
information is critical if we are to understand why the perturbation of DUBs that are supposed to 
have somewhat related functions has different outcomes in intact organisms. Rewards from the 
continued study of DUBs and UPP in the nervous system are expected to be great, both in terms 
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of comprehending basic mechanisms of neuronal physiology, and in understanding and treating 
diseases of the nervous system. 
 The chapters that follow summarize my thesis work and span two DUBs, USP5 and 
ataxin-3. In chapter two, I present data from our studies examining the physiological role of 
USP5 in Drosophila, these results have been published. In chapter three, we examine the role 
that the interaction between pathogenic ataxin-3 and VCP plays in Spinocerebellar Ataxia Type-3 
pathogenesis in a Drosophila model of the disease. 
 31
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Ristic et al. DUBs and the UPP in the nervous system
Table 1 | DUBs in the nervous system.
UCH
UCHL1 Lack of UCHL1 causes gracile axonal dystrophy in mice. Mutations have been linked
to PD and other diseases. An N-terminal truncation of this DUB may prevent PD-like
damage in cultured cells, potentially by reducing oxidative stress. Primary function of
this DUB appears to be mono-Ub maintenance.
Larsen et al., 1998; Setsuie and Wada,
2007; Bilguvar et al., 2013; Kim et al.,
2014
UCHL3 Mutations in mice cause learning and working memory deficits. Also observed are
muscular and retinal degeneration, potentially due to oxidative stress.
Kurihara et al., 2000; Wood et al.,
2005; Sano et al., 2006
UCHL5/UCH37 Reversibly associates with the 19S component of the proteasome and
deubiquitinates proteasome substrates. Uchl5 knockout mice die during development
due to brain malformations. In non-neural tissue, may regulate TGF-β signaling.
Wicks et al., 2005; Al-Shami et al.,
2010; Clague et al., 2013
USP
USP2 Involved in regulating the sensitivity to light of the circadian system in mice by
deubiquitinating the transcription factor BMAL1. This DUB is upregulated in
high-grade gliomas. Pan-neuronal knockdown in Drosophila leads to reduced
locomotion and earlier adult lethality.
Scoma et al., 2011; Tsou et al., 2012;
Tao et al., 2013
USP5 Co-purifies with synaptic 26S proteasome from rat cortex. Recycles mono-Ub by
hydrolyzing unanchored ubiquitin chains. Pan-neuronal knockdown in Drosophila
causes reduced motility and earlier adult death.
Reyes-Turcu et al., 2009; Tai et al.,
2010; Tsou et al., 2012
USP7 Largely functions by preventing the proteasomal degradation of proteins, including
p53 and REST. Brain-specific knockout causes brain malformation and neonatal
lethality in mice, due at least in part to p53-dependent mechanisms.
Li et al., 2002; Huang et al., 2011; Kon
et al., 2011
USP8 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
USP9X Involved in neuronal fate specification and NMJ function. Evidenced to regulate the
degradation of the neurodegenerative disease protein α-synuclein by deubiquitinating
it. May function outside of the UPP.
Huang et al., 1995; Fischer and
Overstreet, 2002; Rott et al., 2011
USP13 Co-purifies with synaptic 26S proteasome from rat cortex. Tai et al., 2010
USP14 Associates reversibly with the 19S proteasome and deubiquitinates proteasome
substrates. Primary role in the nervous system appears to be maintenance of
mono-Ub for reuse. May deubiquitinate specific substrates, including the
neurodegenerative proteins tau and ataxin-3 to suppress their degradation, and the
Wnt signaling regulator Dishevelled to regulate its interaction with partners.
Mutations in mice cause ataxia and lead to abnormal NMJ structure and function,
which is suppressed by reintroducing mono-Ub.
Wilson et al., 2002; Chen et al., 2009,
2011; Lee et al., 2010a; Jung et al.,
2013
USP18 Knockouts in mice cause tremors, loss of balance, convulsions, and premature death.
Anomalies appear to be related to the Ub-like protein ISG15, which USP18 can
de-conjugate.
Ritchie et al., 2002; Knobeloch et al.,
2005
USP22 Its Drosophila ortholog regulates axonal projection of photoreceptor cells. Yi and Ehlers, 2007
USP24 May be involved in PD susceptibility, according to gene linkage analysis. Li et al., 2006
USP25 Overexpressed in human Down syndrome brains. Evidenced to prevent the
proteasomal turnover of the AD-related protein APP.
Valero et al., 1999; Blount et al., 2012
USP30 Opposes parkin-mediated mitophagy by deubiquitinating mitochondria in mammalian
cells. Knockdown in Drosophila dopaminergic neurons suppresses PD-like
degeneration.
Bingol et al., 2014
USP33 Regulates axonal pathfinding during development by regulating the stability or
surface exposure of the axonal guidance receptor Roundabout.
Yuasa-Kawada et al., 2009
USP34 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
(Continued)
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Table 1 | Continued
USP36 Pan-neuronal knockdown in Drosophila leads to reduced locomotion and earlier adult
death.
Tsou et al., 2012
USP39 Glial-restricted knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
USP40 May be involved in PD susceptibility, according to gene linkage analysis. Li et al., 2006
USP46 Mutations in this DUB in mice cause anomalies in circadian rhythm and behavioral
abnormalities during stress. In C. elegans, this DUB regulates lysosomal degradation
of glutamate receptors.
Tomida et al., 2009; Kowalski et al.,
2011; Kowalski and Juo, 2012
USP47 Pan-neuronal knockdown in Drosophila leads to reduced locomotion and early adult
death.
Tsou et al., 2012
USP54 Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
MJD
Ataxin-3 Mutations in it cause the neurodegenerative disease SCA3. Evidenced to cooperate
with several E3 Ub ligases. May assist with the degradation of various UPP
substrates. Suppresses polyglutamine-dependent degeneration in Drosophila.
Costa Mdo and Paulson, 2012; Tsou
et al., 2013
OTU
OTUB1 Found in Lewy bodies in post-mortem PD brains. Xia et al., 2008
OTUD4 Mutations in this DUB and the E3 Ub ligase RNF216 have been linked to syndromic
hypogonadotropic hypogonadism, ataxia, and dementia in humans. Knockdown in
zebrafish causes anomalous development of the eye, optic tectum, and cerebellum.
Margolin et al., 2013
Otulin/Gumby Mutations in the murine version of this DUB, which cleaves linear Ub chains, cause
anomalies in angiogenesis, neuronal, and craniofacial development as a result of
perturbed Wnt signaling.
Rivkin et al., 2013
JAMM
PSMD14 Stoichiometric subunit of the 19S proteasome. Deubiquitinates substrates at the
proteasome. Pan-neuronal knockdown in Drosophila leads to lethality during
development.
Verma et al., 2002; Yao and Cohen,
2002; Clague et al., 2013
EIF3H Pan-neuronal knockdown in Drosophila is developmentally lethal. Tsou et al., 2012
AMSH Knockout mice die young. Neuronal loss is observed in the cerebral cortex and the
hippocampus.
Ishii et al., 2001; Suzuki et al., 2011
deubiquitination at the prot asome is inse sitive to molecules
that block cysteine proteases, whereas a zinc chelator blocks deu-
biquitination, suggesting a metallo-enzyme. Mutations in Rpn11
stabilize UPP substrates and are lethal in yeast. These and other
studies pointed to Rpn11 as the DUB functioning at the pro-
teasome, bridging substrate deubiquitination and degradation
(Verma et al., 2002; Yao and Cohen, 2002).
Work conducted in mammalian cell culture implicated
PSMD14 in maintaining the post-mitotic status of neurons.
RNAi-mediated knockdown of PSMD14 in mouse midbrain and
cortical cultures leads to de novo synthesis of DNA and an increase
in apoptosis (Staropoli and Abeliovich, 2005). The mechanism
behind these observations is unclear, but these data suggest a
critical role for UPP in preventing neurons from re-entering
mitosis. Perhaps disturbance of the UPP (from the perspective of
PSMD14) triggers a general cellular stress response that ultimately
leads to neuronal death. Alternatively, the UPP could be involved
in the continuous turnover of specific factors that induce mitotic
re-entry. Highlighting he importance of PSMD14 to the nervous
system, RNAi-mediated knockdown of its ortholog in neurons in
Drosophila causes larval lethality (Tsou et al., 2012).
PSMD14 is one of very few DUBs with a specific function, in
this case, the removal of poly-Ub chains in a single swoop from
substrates at the proteasome. As it will become clear through the
remainder of this review, it is difficult to categorize most DUBs as
operating in only one step, or acting on only one substrate, path-
way, tissue, or organ. Perhaps PSMD14 is an exception because of
its continuous presence at the 19S subunit, where it is precluded
from interacting with other potential partners. Most other DUBs
do not appear to reside in a single constitutive molecular com-
plex and can thus conduct different functions depending on their
interactions.
UCHL5
This DUB is a member of the UCH sub-family and is also known
as UCH37. Unlike PSMD14, UCHL5 is not a constitutive subunit
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CHAPTER 2:  USP5 IS DISPENSIBLE FOR MONOUBIQUITIN MAINTENANCE IN 
DROSOPHILA
Published: Ristic G, Tsou W-L, Guzi, E, Kanack AJ, Scaglione KM, Todi SV (2016). USP5 is 
dispensable for mono-ubiquitin maintenance in Drosophila. The Journal of Biological Chemistry. 
291(17): 9161-9172. DOI: 10.1074/jbc.M115.703504.
2.1 Introduction
 Ubiquitination is an important post-translational modification of numerous proteins in the 
cell, where it is involved in the regulation of various processes ranging from DNA transcription 
to protein degradation. Three different classes of enzymes are responsible for carrying out this 
modification: E1 (ubiquitin activating enzymes), E2 (ubiquitin conjugating enzymes) and E3 
(ubiquitin ligases) (Pickart, 2000). Through the coordinated action of these proteins, a ubiquitin 
molecule is conjugated most commonly to a lysine residue of a substrate protein through an 
isopeptide bond. Because ubiquitin itself has seven lysine residues, which are available for 
isopeptide bond formation, and because ubiquitin moieties can also be connected “head-to-tail”, 
ubiquitin chains of different conformations are generated (Pickart and Fushman, 2004; Ristic et 
al., 2014). Different chains impart specific outcomes on the fate of the protein to which they are 
conjugated. For example, K48-linked ubiquitin targets proteins for proteasomal degradation, 
whereas K63-linked species have been associated with autophagy and other non-proteasomal-
dependent events (Thrower et al., 2000; Komander et al., 2009; Hao et al., 2013; Nathan et al., 
2013).  
 Ubiquitination and ubiquitin recycling are tightly controlled in order to fine-tune the 
process, to bring a cellular event to an end, to regulate protein fate and to recycle ubiquitin for 
reuse. The reversal of ubiquitination is carried out by a class of proteases known as 
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deubiquitinating enzymes, deubiquitinases, or DUBs. DUBs are divided into five families, based 
on similarity in their catalytic domains: Ubiquitin Specific Proteases, Ubiquitin C-Terminal 
Hydrolases, Machado-Joseph Disease Proteins, Otubain Proteases and the JAB1/MPN/Mov34 
Metalloenzymes. Nearly 100 genes encoding DUBs have been identified in humans, but the 
functions of many of them remain to be discovered (Komander et al., 2009; Todi and Paulson, 
2011; Clague et al., 2012; Clague et al., 2013; Ristic et al., 2014). Ubiquitin Specific Protease 5 
(USP5, also known as Isopeptidase T) is one DUB whose structural properties are well 
understood. USP5 is reportedly an exopeptidase that hydrolyzes isopeptide bonds in poly-
ubiquitin from the free carboxy-terminal end to produce mono-ubiquitin, which can then be re-
conjugated to substrate proteins (Wilkinson et al., 1995; Reyes-Turcu et al., 2006; Reyes-Turcu 
et al., 2008). Depletion of USP5 orthologues in yeast and in mammalian cells leads to 
accumulation of unanchored ubiquitin chains and causes proteasomal inhibition (Amerik et al., 
1997). These and other findings place USP5 at the proteasome: before a protein is degraded by 
the proteasome, the ubiquitin chain signaling its degradation is removed en bloc by another 
DUB, RPN11/POH1, leaving unanchored poly-ubiquitin. USP5 processes this unanchored chain 
to yield mono-ubiquitin (Clague et al., 2013; Ristic et al., 2014). Thus, this DUB is thought of as 
a ubiquitin recycler, helping to maintain a mono-ubiquitin pool for reutilization (Komander et al., 
2009; Grou et al., 2015; Kovacs et al., 2015). Most ubiquitin is found in conjugated form in 
various tissues tested, leaving only a small portion available in the unconjugated, mono-ubiquitin 
pool (Kaiser et al., 2011; Oh et al., 2013; Kovacs et al., 2015). As there is persistent demand for 
protein modification through ubiquitination, there is a constant need to generate mono-ubiquitin 
through recycling, or through new synthesis via ubiquitin-encoding genes. 
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 It is not entirely clear whether a primary role for USP5 in vivo is mono-ubiquitin 
maintenance. Here, we tested this possibility in the fruit fly Drosophila melanogaster, whose 
USP5 is necessary during development (Tsou et al., 2012; Wang et al., 2014; Kovacs et al., 
2015). Our biochemical and genetic experiments indicate that Drosophila USP5 is not necessary 
for maintaining a ready pool of mono-ubiquitin in vivo. 
2.2 Materials and Methods   
Drosophila lines and related procedures:  RNAi-1 and RNAi-2 targeting USP5 were from the 
Vienna Drosophila RNAi Center (VDRC) (Dietzl et al., 2007). These two fly lines contain the 
same targeting sequence inserted at different chromosomal sites. RNAi-3, the UAS-mono-
ubiquitin over-expression line, and the Gal80ts line were from the Bloomington Drosophila Stock 
Center (BDSC). The UAS-CL1-GFP line was a generous gift from Dr. Udai Pandey, University 
of Pittsburgh, the actin-Gal4 and the sqh-Gal4 lines were a generous gift from Dr. Daniel Eberl, 
University of Iowa, and the da-Gal4 line was generously donated by Dr. R. J. Wessells at Wayne 
State University. Flies were maintained at 25˚C and ~40-60% humidity in regulated diurnal 
environments. Where noted in figures and legends, flies were maintained at 18˚C and 30˚C, 
~40-60% humidity under diurnal cycle for Gal80 experiments. 
SDS-PAGE, Western Blotting and Quantification: Larvae, pupae, or flies, as indicated in 
figures and legends, were homogenized in boiling SDS lysis buffer (50mM Tris pH 6.8, 2% 
SDS, 10% glycerol and 100 mM dithiothreitol (DTT)), sonicated, boiled for 10 minutes, 
centrifuged for 10 minutes at 13000 X g at room temperature, and loaded onto SDS-PAGE gels, 
electrophoresed at 160-170 V and transferred onto polyvinylidene difluoride (PVDF) membrane 
(Bio-Rad) for western blotting, as previously described (Blount et al., 2012; Tsou et al., 2012; 
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Blount et al., 2014; Tsou et al., 2015a; Tsou et al., 2015b). 10 larvae, 5 pupae, or 5 adults were 
collected per group in 15 µL lysis buffer per larva, 20 µL per pupa, or 30 µL buffer per adult. For 
direct blue staining of PVDF membranes, 0.1% DB71 (Sigma-Aldrich) stock solution in ultra-
pure water was dissolved in 40% ethanol and 10% acetic acid solvent to a final concentration of 
0.01%, membrane was immersed for 5 minutes, rinsed briefly with solvent, then ultra-pure 
water, and air dried. Coomassie blue staining was conducted as described before (Scaglione et 
al., 2011; Scaglione et al., 2013). Western blots were imaged with a charge-coupled device-
equipped VersaDoc 5000MP system (Bio-Rad) (Blount et al., 2012; Blount et al., 2014). 
Quantification of signals from sub-saturated blots was conducted with Quantity One Software 
(Bio-Rad) with universal background subtraction. Experimental lanes were normalized to their 
respective controls. Student’s t-tests (one- or two-tailed, as appropriate) or ANOVA with Tukey’s 
post-hoc correction were used for statistical comparisons. 
Antibodies: Anti-Ubiquitin (DAKO rabbit polyclonal 1:500, catalog #Z0458), P4D1 (mouse 
monoclonal 1:500, Santa Cruz Biotechnology, catalog # SC2017, used only in figure 3C), anti-
Tubulin (mouse monoclonal 1:5,000, Sigma-Aldrich, catalog # T5168), anti-Actin (JLA20 
mouse monoclonal 1:500, Developmental Studies Hybridoma Bank), anti-HA (Y11, rabbit 
polyclonal, 1:1000, Santa Cruz Biotechnology, catalog # SC805), anti-GFP (mouse monoclonal, 
1:1000, Roche, catalog # 11814460001), anti-CHIP (rabbit monoclonal, 1:1000, Cell Signaling 
Technology, catalog # 2080S), anti-HSP70 (mouse monoclonal, 1:1000, Rockland, catalog # 
200-301-A27), anti-Cyclin A (A12 mouse monoclonal, 1:100, Developmental Studies 
Hybridoma Bank), anti-Sin3 (rabbit monoclonal, 1:2000), anti-VCP (rabbit monoclonal, 1:1000, 
Cell Signaling Technology catalog # 2648S) peroxidase-conjugated secondary antibodies (goat 
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anti-rabbit and goat anti-mouse, 1:5,000; Jackson Immunoresearch). Sin3 antibody was a 
generous gift from Dr. Lori Pile, Wayne State University (Pile and Wassarman, 2000). The 
JLA20 and A12 antibodies were procured from the Developmental Studies Hybridoma Bank, 
created by the NICHD of the NIH and maintained at The University of Iowa, Department of 
Biology, Iowa City, IA 52242. JLA20 was deposited to the DSHB by Lin, J.J.-C. A12 was 
deposited to the DSHB by Lehner, C.F.  
Cloning and protein purification: DmUSP5 was cloned in two fragments from a Drosophila 
w1118 cDNA library generated in our lab. Fragment A was PCR-amplified by using forward 
primer: 5’-GTT TAT GAG AAA AGA GCT GCC TAC A -3’ and reverse primer: 5’- CAA TAC 
TGC TGT ACT TTC CCG ACT -3’. Fragment B was PCR-amplified by using forward primer: 
5’- GGC AAC TCC TGC TAC ATA AAC AG -3’ and reverse primer: 5’- CGA ATA ATA TTA 
GCT TGT GGG ACT G -3’. The fragments were ligated and inserted into pCR Blunt II TOPO 
vector (ThermoFisher). Full length DmUSP5 was then sub-cloned into pGEX6p1 (GE 
Healthcare). The human USP5 construct was purchased from Addgene, a generous gift of the 
Arrowsmith Lab (plasmid #25299). 
 DmUSP5 in pGEX6p1 and human USP5 in pET28 were transformed into BL21 E. coli. 
Individual colonies were grown at 37ºC overnight in LB with ampicillin or kanamycin, as 
needed. 10 mL was used to inoculate 500 mL of LB and was grown for an additional 3 hours at 
37ºC. Protein expression was induced by 0.5mM of isopropyl-1-β-D-galactopyranoside (A.G. 
Scientific) for 2 hours at 30ºC. DmUSP5 was purified by GST-pulldown. Bacterial cells were 
pelleted by centrifugation and resuspended in NETN lysis buffer (50mM Tris pH 7.5, 150mM 
NaCl, 0.5% NP40), sonicated, then centrifuged for 20 minutes at 4ºC. 250µL of glutathione-
 38
sepharose beads (GE Healthcare) were washed with NETN, lysates were added to beads and 
tumbled at 4ºC. Beads were then washed with NETN buffer thrice followed by two PBS washes. 
Prescission Protease (GE Healthcare) with 1% DTT was used to elute the bead-bound protein. 
HIS-tagged human USP5 was purified with nickel beads. Pelleted bacterial cells were 
resuspended in Buffer A (50mM Tris, pH 7.5, 150 mM NaCl), sonicated and centrifuged. 400µL 
of Nickel nitrilotriacetic acid beads (Qiagen) were washed in Buffer A and incubated with 
lysates. Beads were then rinsed twice each with Buffers A, B (50 mM Tris, pH 7.5, 1M NaCl, 
20mM Immidazole) and C (50mM Tris, pH 7.5, 100mM NaCl, 20mM Imidazole, 0.5% TX-100). 
Protein was eluted with Buffer C containing 300mM imidazole and 1% DTT.  Catalytically 
inactive DmUSP5 was created using the QuikChange mutagenisis kit (Agilent) (Blount et al., 
2014). The catalytic cysteine at position 341 was mutated to an alanine. Recombinant protein 
concentration was determined using NanoDrop and coomassie blue staining of SDS-PAGE gels. 
In vitro reactions: 50 nM of recombinant DmUSP5 or human USP5 was added to kinase buffer 
(0.5M Tris pH 7.5, 0.5M KCl, 0.2% DTT) with 1 µM of ubiquitin chains with specific linkages 
for a total reaction volume of 60 µL. Reactions were incubated at 37ºC for human USP5 or 25˚C 
for fly USP5 and 15 µL were taken from each reaction at the indicated times points. Reaction 
was stopped by the addition of 10 µL sample loading buffer and boiled for two minutes. DUB 
reactions were also repeated at 37ºC for Drosophila USP5, with similar results to those at 25˚C. 
Ubiquitin chains were purchased from Boston Biochem.  
 CHIP and HSP70 ubiquitination was carried out as previously described (Scaglione et al., 
2011; Scaglione et al., 2013), for 1 hour at 37ºC in 100 µL kinase buffer. Ubmix (2.5 mM ATP, 2.5 
mM MgCl2, 100 nM Ube1 and 250 µM ubiquitin), 1 µM E2 (Ube2w for mono-ubiquitinated 
 39
CHIP, or UbcH5c for poly-ubiquitinated CHIP and HSP70), 1 µM CHIP, and 1 µM HSP70. 
Reactions were stopped by the addition of excess EDTA, and 50 nM (final) DmUSP5 or human 
USP5 was added to the complex. Reaction time points were separated on 4-20% poly-acrylamide 
gels and analyzed by western blotting.  
Quantitative, Real-Time PCR: Total RNA was extracted from larvae or pupae using TRIzol 
reagent (Invitrogen), followed by treatment with TURBO DNase (Ambion) to eliminate 
contaminating DNA. High Capacity Kit (ABI) was used to perform reverse transcription. 
Messenger RNA levels were quantified with PlusOne real-time quantitative system using Fast 
SYBR Green (ABI). rp49 was used as a control. All qRT-PCR primers are listed in table 2.1. 
2.3 Results 
2.3.1 Drosophila and human USP5 disassemble unanchored ubiquitin chains similarly in vitro 
 CG12082 is the Drosophila gene whose product most closely aligns with mammalian 
USP5 (Tsou et al., 2012). Like its human counterpart, CG12082 contains the Ubiquitin Specific 
Protease (USP) domain, the Ubiquitin Associated Domains (UBAs) that bind to ubiquitin 
moieties in poly-ubiquitin chains, and a zinc finger-like region (Falquet et al., 1995; Wilkinson et 
al., 1995; Raasi et al., 2005; Reyes-Turcu et al., 2006; Reyes-Turcu et al., 2008; Avvakumov et 
al., 2012) (figure 2.1A).  
 Recombinant, human USP5 has been reported to hydrolyze poly-ubiquitin chains of 
different linkages in vitro (Falquet et al., 1995; Wilkinson et al., 1995; Raasi et al., 2005; Reyes-
Turcu et al., 2006; Reyes-Turcu et al., 2008; Avvakumov et al., 2012). We began our studies of 
Drosophila USP5 (DmUSP5) by comparing ubiquitin chain cleavage preferences between it and 
the human counterpart in vitro. We carried out deubiquitination reactions at 37˚, optimal for 
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human USP5, and 25˚C, optimal for Drosophila USP5, although the same results were also 
obtained at 37˚C (figure 2.1 and data not shown). We observed that DmUSP5 and human USP5 
both hydrolyze unanchored poly-ubiquitin chains of different linkages (figure 2.1B). The 
recombinant proteases have different proficiencies: K11, K48, K63 and linear (head-to-tail) 
species were cleaved more rapidly than K6- and K29-linked di-ubiquitin. Both DUBs were also 
able to cleave rapidly di- as well as tetra-ubiquitin chains (figure 2.1B). We noticed that as K6 
and K33 di-ubiquitin disappear, mono-ubiquitin does not always seem to mirror the reduction of 
the substrate species (figure 2.1B). This is not because of indiscriminate cleaving of ubiquitin, 
e.g. from the presence of non-ubiquitin proteases, as the chains are stable over time in the 
absence of DmUSP5 (figure 2.1C); instead, it might result from reduced antibody affinity 
toward ubiquitin with only specific lysines present, which could affect epitope exposure/
recognition in di- vs. mono-ubiquitin. Based on these data, we conclude that the Drosophila and 
human USP5 enzymes have similar catalytic affinity toward most ubiquitin linkages. As shown 
in figure 1D, the catalytic cysteine at position 341 of the Drosophila USP5 is necessary for its 
protease activity. 
 There is evidence that mammalian USP5 can disassemble not only unanchored chains, 
but that it can also deubiquitinate specific substrates (Scaglione et al., 2011; Garcia-Caballero et 
al., 2014). We thus examined whether DmUSP5 and human USP5 could remove ubiquitin from 
ubiquitinated, recombinant proteins in an in vitro setting. We used a previously published 
protocol to ubiquitinate CHIP (an E3 ubiquitin ligase) and HSP70 (the molecular chaperone 
(Scaglione et al., 2011)). As shown in figure 1E, both human and Drosophila USP5 
deubiquitinate mono-ubiquitinated and poly-ubiquitinated CHIP, but do not affect ubiquitinated 
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Figure 2.1: Conserved catalytic activity in vitro between Drosophila and human USP5.
A) DmUSP5 closely resembles its human counterpart. 827 amino acid residues long, this DUB contains 
two ubiquitin-associated (UBA) domains, a Ubiquitin Specific Protease (USP) domain and a zinc-finger 
(ZnF) area. The catalytic cysteine of DmUSP5 is at position 341 (Ref. 19).  
B-D) Western blots of in vitro deubiquitinating reactions containing either 50 nM human (h) USP5 or 50 
nM Drosophila (Dm) USP5 with 1µM ubiquitin chain of the indicated linkage in reaction buffer. Samples 
were run on 18% (B) or 15% acrylamide gels  (C, D) and analyzed by western blotting. For panel D, 
where indicated 50 nM catalytically inactive recombinant DmUSP5 was used. Mutation is C341A. Blots 
are representative of experiments conducted at least three independent times, with similar results. Note 
that in K29-only chains there are also higher (bracketed) species, most likely tri- and tetra-ubiquitin as 
well as higher-order forms, which disappear over time. Their cleavage probably supplants di-ubiquitin 
K29 species as the experiment progresses. Such higher-order forms are not present as much or at all in 
the other ubiquitin species used  
E) Western blots of in vitro deubiquitinating reactions with ubiquitinated proteins. CHIP and HSP70 were 
ubiquitinated as described in the Experimental Procedures. The ubiquitination reaction was stopped 
with excess EDTA, then 50 nM (final concentration) recombinant human (hUSP5) or Drosophila (Dm) 
USP5 was added to the mix. Samples were collected at the indicated time points after the addition of 
the DUB, resolved in 4-20% SDS PAGE gels and blotted as indicated. Blots are representative of 
deubiquitination reactions conducted at least three independent times with similar results.
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HSP70. These findings support the notion that USP5 can act on specific substrates. 
2.3.2 DmUSP5, important during fly development, is dispensable in adults 
 In order to progress toward our major goal, to determine whether DmUSP5 is required 
for mono-ubiquitin maintenance in vivo in Drosophila, we next tested the importance of this 
DUB during development and in adults. Our group and others previously reported that RNA-
interference (RNAi)-dependent knockdown of DmUSP5 and mutations in its gene lead to 
developmental lethality in the fruit fly (Tsou et al., 2012; Wang et al., 2014; Kovacs et al., 2015). 
To examine whether this DUB is also important in adults, we employed the power of the Gal4-
UAS system (Brand and Perrimon, 1993).  
We began by testing the efficacy of various RNAi lines targeting DmUSP5. DmUSP5 is 
expressed throughout the fly (Wang et al., 2014); therefore, we targeted this protease in the 
whole the organism by using the ubiquitous drivers sqh-Gal4, actin-Gal4, or da-Gal4, with 
similar results. We used three different RNAi lines specific for DmUSP5 that target different 
sites of its mRNA. RNAi-1 and -2 were generated through P-element-mediated insertions of a 
UAS-based transgene (Dietzl et al., 2007), whereas RNAi-3 was generated through site-specific 
recombination by using the phiC31 integrase (Groth et al., 2004). 
 Knocking down DmUSP5 in the whole fly using ubiquitous drivers causes third instar 
larval lethality with RNAi-3 and mid pupal lethality with RNAi-1 and -2, compared with their 
respective host line controls (figure 2.2A). Death at third instar larval stage is the same as 
observed with DmUSP5 null mutation (Wang et al., 2014). The level of knockdown obtained by 
the ubiquitous sqh-Gal4 driver was determined through quantitative real-time (qRT)-PCR and is 
shown in figure 2.2B. We consistently observe a more pronounced phenotype with RNAi-3 
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compared with the two other RNAi lines. This is most likely due to RNAi-3 reducing the levels 
of DmUSP5 mRNA more strongly than RNAi-1 and -2 (figure 2.2B). 
 While the importance of DmUSP5 during development is clear, it has not been reported 
before whether this DUB is also required in later stages, including adults. We next utilized a 
ubiquitously-expressed, temperature-sensitive Gal80ts construct (McGuire et al., 2003) to control 
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Figure 2.2: DmUSP5 is necessary during fly development but not in adults.
A) Summary of phenotypes when DmUSP5 is knocked down throughout the fly. Flies were 
heterozygous for all transgenes. Results and percentages are from independent crosses conducted at 
least 10 times each, with similar outcomes. No larvae (RNAi-3) or pupae (RNAi-1, -2) varied from the 
indicated stage of death when DmUSP5 was knocked down.
B) Quantitative real time (qRT)-PCR results from flies expressing DmUSP5-RNAi driven by sqh-Gal4. 
Flies were heterozygous for UAS-RNAi and sqh-Gal4. Control: sqh-Gal4 on the background host line 
for each RNAi. Black font P-values compare RNAi-1, -2 and -3 to the control line. Red font P-values 
compare RNAi-2 and RNAi-3 to RNAi-1. P-values are from ANOVA with Tukey’s post-hoc correction. 
Error bars: s.d. N=6 independently conducted experiments. 
C) Diagram summarizing the mechanism of Gal80. Please see text for additional details for this method.
D) Timeline summarizing when flies were moved from the permissive to the restrictive Gal80 
temperature, and the effect of switching on Gal4-driven knockdown of DmUSP5. Driver was sqh-Gal4 
and the RNAi line was UAS-RNAi-3. Flies were heterozygous for all transgenes. Results are from at 
least N=5 independent crosses for each point, with similar results. At least 200 adults flies per group 
were monitored for the longevity experiment where adults successfully eclosed from their pupal cases.
E) qRT-PCR from adult flies maintained at the restrictive Gal80 temperature for either 1 or 28 days, 
showing decreased levels of DmUSP5 mRNA when Gal4 is active. P value is from Student’s t-test. 
Error bar: s.d. N=5 independent replicates. All flies were heterozygous for sqh-Gal4, Gal80 and UAS-
RNAi-3 targeting DmUSP5.
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when UAS-RNAi-3 targeting DmUSP5 is expressed (figure 2.2C). Gal80 binds to Gal4 and 
prevents this transcription factor from driving the expression of UAS-based transgenes, in this 
case, UAS-RNAi-3. When flies containing the Gal80 construct alongside RNAi-3 and the 
ubiquitous sqh-Gal4 driver are placed at the permissive temperature (18˚C), Gal80 impedes 
RNAi-3 expression. When flies are moved to the Gal80 restrictive temperature (30˚C), sqh-Gal4 
can drive expression of UAS-RNAi-3.  
 We began by examining the effect of DmUSP5 knockdown when RNAi-3 targeting its 
mRNA is enabled on from the beginning (figure 2.2D); these flies die as third instar larvae, in 
accordance with data in figure 2.2A. Induction of USP5 knockdown beginning at larval and 
pupal stages results in death during pupal and pharate adult stages, respectively (figure 2.2D). 
However, when developing flies are moved to the restrictive Gal80 temperature as soon as they 
enter the pharate adult stage, these flies eclose normally and live a life span not different from 
those of their control siblings. When adults are moved to the restrictive temperature as soon as 
they eclose from the pupal case, they also survive and live a life span not different from controls 
that do not express RNAi-3 (figure 2.2D). Figure 2E confirms reduction of DmUSP5 mRNA 
when Gal80 is restricted. Based on these findings, USP5 is required during development, but is 
not critically important in adults.  
2.3.3 DmUSP5 knockdown leads to increased conjugated ubiquitin species without depleting 
mono-ub 
 USP5 is considered to be primarily a ubiquitin chain dismantler for the purpose of mono-
ubiquitin recycling (Komander et al., 2009; Ristic et al., 2014; Grou et al., 2015; Kovacs et al., 
2015). To examine the effect of DmUSP5 knockdown on overall ubiquitin species in developing 
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flies, we performed western blotting from whole larval and pupal lysates and probed for 
ubiquitin (figure 2.3A).  
 Lysates were prepared from developing flies harvested before death. Larvae were from 
crosses where UAS-RNAi-3 was driven by sqh-Gal4, while pupae were from UAS-RNAi-1 and 
-2, also driven by sqh-Gal4. Compared with their controls, containing sqh-Gal4 on the respective 
host background of the UAS-RNAi transgenes, but without DmUSP5 knockdown, we observe 
increased levels of conjugated ubiquitin (brackets in figure 2.3A; quantified in 2.3B). 
Interestingly, we do not observe depletion of mono-ubiquitin alongside higher levels of 
conjugated ubiquitin (figure 2.3A, 2.3B). In fact, we observe increased levels of mono-ubiquitin 
when DmUSP5 is knocked down. The important point, however, is that DmUSP5 knockdown in 
the fruit fly does not lead to decreased levels of mono-ubiquitin. We used two different anti-
ubiquitin antibodies to assay conjugated and mono-ubiquitin in fly lysates, with similar results 
(figure 2.3A, 2.3C, and other supportive data not shown). Based on these outcomes, knockdown 
of DmUSP5 does not lead to a reduction of mono-ubiquitin in developing flies. 
 Intrigued by a lack of depletion of mono-ubiquitin when DmUSP5 is knocked down, we 
examined why this may be the case. Mono-ubiquitin is maintained through de novo synthesis 
from genes that encode it as a fusion protein to additional ubiquitin moieties or to other proteins,  
and by being cleaved from ubiquitin chains or substrates (Grou et al., 2015). We wondered 
whether knockdown of DmUSP5 leads to increased transcription of ubiquitin-encoding genes in 
Drosophila. We assessed by qRT-PCR the levels of different ubiquitin-encoding genes in the fly: 
the mono-ubiquitin encoding genes CG2960 and CG5271, which encode ribosomal fusion 
proteins RpL40 and RpS27A, respectively, and two poly-ubiquitin encoding genes, CG32744 
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and CG11624. Another gene, CG11700, which closely aligns with CG32744 (Lu et al., 2013), 
was assayed through CG32744 primer sets. We identified these genes by using the FlyBase 
resource, through our own alignments with mammalian ubiquitin-encoding genes through 
BLASTp, and based on previously published work (Lu et al., 2013). Based on qRT-PCR results, 
there is no overall increase in ubiquitin gene expression when DmUSP5 is knocked down 
everywhere in the fly (figure 2.4A). In fact, in some instances we observe a statistically 
significant decrease in ubiquitin gene expression. These data suggest that lack of depletion of 
mono-ubiquitin when DmUSP5 is knocked down is not due to increased ubiquitin production at 
the transcript level.  
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Figure 2.3: Knockdown of USP5 does not deplete mono-Ub.
A) Western blots from larval or pupal lysates when DmUSP5-RNAi was driven by sqh-Gal4. 4-20% 
gradient gels. All flies were heterozygous for UAS-RNAi (1, 2, or 3) and sqh-Gal4. Brackets: conjugated 
ubiquitin species that were quantified for panel (B). Control: Gal4 driver on the background host line of 
RNAi.
B) Quantifications of blots in panel (A) and other similar, independent experiments. P-values are from 
Student’s t-tests. Error bars: s.d. N=4 independently conducted experiments.
C) Western blots of whole larval or pupal lysates where sqh-Gal4 was driving the expression of UAS-
RNAi-3 (larvae) or UAS-RNAi-2 (pupae). 4-20% gradient gels. Anti-ubiquitin antibody used was different 
than the one in the other panels. This anybody (monoclonal P4D1) also shows increased levels of 
conjugated ubiquitin (bracket) while mono-ubiquitin is also not depleted, similar to what we observe with 
the other antibody, shown in panel A and in the rest of the figures of this manuscript.
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 Next, we examined the expression levels of other DUBs that have been linked to mono-
ubiquitin maintenance and that function, at least in part, by associating with the proteasome, 
where DmUSP5 is also proposed to act: USP14, RPN11, and UCH-L5 (Tsou et al., 2012). Based 
on qRT-PCR, reduced DmUSP5 mRNA levels coincide with mildly, but statistically significantly, 
increased levels of USP14, RPN11 and UCH-L5 (figure 2.4B). The levels of expression of these 
DUBs during fly development and in adults vary from moderate to very high, similar to the 
expression of DmUSP5 (transcriptional data on FlyBase.org). This could suggest that some 
DmUSP5 functions might be complemented by increased transcription of these other DUBs, 
even though ultimately they fail to suppress lethality caused by the absence of DmUSP5 during 
development. Increased transcription of endogenous USP14, a DUB demonstrated to maintain 
mono-ubiquitin in mice (Anderson et al., 2005; Chen et al., 2009; Chen et al., 2011; Hallengren 
et al., 2013), may account for mono-ubiquitin not being depleted when DmUSP5 is knocked 
down in developing flies. When we tested if exogenous USP14 alleviates lethality caused by 
knockdown of DmUSP5, we found that this was not the case (figure 2.4C): USP14 over-
expression alongside ubiquitous DmUSP5 knockdown results in developmental lethality at the 
same stage as DmUSP5 knockdown without exogenous USP14. Over-expression of USP14 by 
itself is not detrimental to the fly (data not shown). 
 Lastly, we used a UAS-based, HA-tagged mono-ubiquitin transgenic fly line to over-
express wild type ubiquitin (Lee et al., 2009). Expression of ubiquitin through this line leads to 
an overall increase in levels of conjugated ubiquitin in intact flies (figure 2.5A). Importantly, as 
shown in the right portion of figure 2.5A, the HA-tagged mono-ubiquitin that we over-express is 
conjugated in flies (also see figure 2.5C). Mono-ubiquitin expression simultaneously with 
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DmUSP5 knockdown, however, does not affect the stage at which developing flies die (figure 
2.5B). Thus, lethality caused by DmUSP5 knockdown in Drosophila is unlikely to be due to lack 
of mono-ubiquitin available for conjugation to various proteins. As shown in figure 5C, 
exogenous ubiquitin does not lead to an appreciable difference in ubiquitin species observed by 
western blotting when DmUSP5 levels are reduced. Collectively, the data in figures 3-5 lead us 
to conclude that DmUSP5 is not necessary for mono-ubiquitin maintenance in Drosophila. 
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Figure 2.4: Ub-expressing genes are not upregulated when DmUSP5 is knocked down.
A) qRT-PCR results examining the expression of fly ubiquitin genes when the noted DmUSP5-RNAi 
constructs were driven by sqh-Gal4. P-values are from Student’s t-tests. Error bars: s.d. N=3 
independently conducted experiments. Flies were heterozygous for driver and RNAi lines. Control: sqh-
Gal4 on the host backgrounds of RNAi and at the same stage as RNAi lines (mid pupae for RNAi-1 and 
RNAi-2, third instar larvae for RNAi-3).
B) qRT-PCR analyses of different Drosophila DUBs when DmUSP5 is knocked down using RNAi-3. All 
flies were heterozygous for UAS-RNAi-3 and sqh-Gal4, except for the control group, which contained 
sqh-Gal4 on the host background of RNAi-3. P-values are from Student’s t-tests. Error bars: s.d. N=4 
independently conducted experiments. Red boxes: proteasome-associated DUBs.
C) Summary of results when UAS-USP14 is over-expressed in Drosophila while DmUSP5 is knocked 
down using RNAi-1. All flies were heterozygous for the transgenes. Driver: sqh-Gal4. Summary is from 
at least 8 independent crosses, with similar results. No pupae varied from the indicated stage of death 
when DmUSP5 was knocked down.
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2.3.4 Accumulation of conjugated ubiquitin species during DmUSP5 knockdown is an early 
event 
 Results shown in the previous figures were from samples collected preceding larval 
(RNAi-3) or pupal (RNAi-1, -2) death when DmUSP5 is knocked down. In order to examine 
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Figure 2.5: Mono-Ub expression does not suppress lethality caused by knockdown of DmUSP5.
A) Western blots from flies expressing UAS-mono-ubiquitin, driven by sqh-Gal4. Mono-ubiquitin is HA-
tagged. Flies were heterozygous for all transgenes. Control: sqh-Gal4 on the background line of UAS-
mono-Ub. Shown are blots from three independent experiments, separated by dotted lines. Left set of 
blots was electrophoresed on a 15% SDS PAGE gel; the rest were electrophoresed on 4-20% gels. Red 
numbers show conjugated protein levels compared to controls. Blue numbers show mono-ubiquitin 
levels compared to controls. For the right set of blots, which are from the same experiment: HA-tagged 
ubiquitin is incorporated into conjugated ubiquitin species. Note that the anti-HA antibody shows 
multiple non-specific bands in the lane without mono-ubiquitin over-expression.
B) Summary of results when UAS-mono-ubiquitin is over-expressed in Drosophila while DmUSP5 is 
knocked down using RNAi-1 or RNAi-3. All flies were heterozygous for the transgenes. Driver: sqh-
Gal4. Summary is from at least five independent crosses, with similar results. No larvae (RNAi-3) or 
pupae (RNAi-1) varied from the indicated stage of death when DmUSP5 was knocked down.
C) Western blots from pupae expressing RNAi-1, driven by sqh-Gal4, in the absence or presence of 
UAS-mono-ubiquitin co-expression. Flies were heterozygous for all transgenes. Blots are representative 
of experiment conducted independently at least five times, with similar results. In anti-HA blot, note 
again the presence of non-specific bands in the absence of the HA-Ubiquitin transgene. 4-20% gradient 
gel.
 50
more temporally the changes in ubiquitin species when DmUSP5 levels are reduced, we 
analyzed larvae and pupae of different stages when DmUSP5 is knocked down through RNA-1 
or -2, which cause pupal death. As summarized in figure 2.6, when DmUSP5 is knocked down 
accumulation of conjugated ubiquitin species begins at least as early as third instar larvae and 
continues through early and mid pupal stages, when they die. This increase in conjugated species 
is accompanied by an increase in mono-ubiquitin that appears more robust over time (figure 
2.6). 
2.3.5 DmUSP5 knockdown leads to impaired proteasome activity 
 Excess ubiquitin chains can compete for proteasomal binding with substrates destined for 
degradation, thereby impairing ubiquitin-dependent proteasome activity (Beal et al., 1996; 
Amerik et al., 1997; Thrower et al., 2000). As shown in earlier figures, there is an accumulation 
of conjugated ubiquitin species that results from knocking down DmUSP5 throughout the fly. 
Could these species coincide with impaired proteasome function? To examine this possibility, we 
used a reporter of ubiquitin-dependent proteasome function, CL1-GFP. This construct consists of 
a GFP moiety fused to the CL1 degron, a signal which targets GFP for proteasomal degradation 
through ubiquitination (Bence et al., 2001; Bennett et al., 2005). We used the ubiquitous driver, 
da-Gal4, to express the reporter throughout the fly while simultaneously knocking down USP5 
with RNAi-1. da-Gal4 also leads to death at mid pupal stages with RNAi-1 and -2, similar to 
what we observe with the other driver, sqh-Gal4.  As the blots in figure 2.7A show, there is in an 
increase in CL1-GFP protein level when DmUSP5 is knocked down compared with its 
respective, no knockdown control. Increased levels of CL1-GFP protein when DmUSP5 is 
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reduced are not due to higher CL1-GFP mRNA (figure 2.7B), indicative of impaired ubiquitin-
dependent proteasomal activity. 
 We then examined the levels of endogenous proteins that are proteasome substrates: 
cyclin A (Chen et al., 2004), and Sin3 (whose orthologue in mammals is degraded by the 
proteasome, (Kong et al., 2010)). None of these proteins has been linked to DmUSP5 so far. We 
also tested the protein levels of VCP/p97, whose expression is induced when proteasome 
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Figure 2.6: Conjugated ubiquitin accumulates early when DmUSP5 is knocked down.
A) Western blots of larval and pupal lysates (17% gel) when DmUSP5-RNAi-1 or -2 were driven by sqh-
Gal4. Samples were collected during three stages of development, as noted. Flies were heterozygous 
for RNAi and sqh-Gal4. Control: sqh-Gal4 on the host background of RNAi. Direct blue staining shows 
total protein loaded.
B) Quantifications of western blots from (A) and other similar, independent experiments. P-values are 
from Student’s t-tests. Error bars: s.d. N=4 independently conducted experiments.
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function is reduced (Lundgren et al., 2005). As indicated by data in figure 2.7C-E, knockdown of 
DmUSP5 leads to statistically significantly higher levels of each of these endogenous proteins in 
developing flies. Based on data in figure 2.7, we conclude that ubiquitin-dependent proteasome 
activity is inhibited by reduced levels of DmUSP5 in Drosophila. 
2.4 Discussion 
 Ubiquitination is a critical regulator of most cellular pathways. Therefore, the process of 
protein ubiquitination and ubiquitin availability both are carefully monitored (Pickart, 2000; 
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Figure 2.7: Knockdown of DmUSP5 causes impairment of proteasome activity.
A, C-E) Left: Western blot of pupal lysates where the ubiquitous driver da-Gal4 (A) or sqh-Gal4 (C-E) 
express DmUSP5 UAS-RNAi-1 throughout the fly. RNAi Ctrl: ubiquitous driver for each panel on the 
isogenic background of RNAi-1. Panels A and B: UAS-CL1-GFP is also expressed in these pupae. 
Panels C-E: no UAS-CL1-GFP is present. Right: Quantification of data from each western blot shown 
and other, independently conducted experiments. P-values are from Students t-tests. Error bars: s.d. 
N≥3 independently conducted experiments for each panel. Arrows in panel D: Sin3 has different 
isoforms, both of which are detected by this antibody. 4-20% gradient gels.
B)qRT-PCR results from pupae with the same genotype and age as in panel A. N=3 independent 
experiments. Error bar: s.d. P value is from Student’s t-test.
 53
Pickart and Fushman, 2004; Shabek and Ciechanover, 2010; Ristic et al., 2014). Important 
regulators of protein ubiquitination are the DUBs, one of which, USP5, has been proposed to 
function in part by maintaining mono-ubiquitin (Komander et al., 2009; Ristic et al., 2014; Grou 
et al., 2015; Kovacs et al., 2015). Here, our primary question was whether the fly orthologue of 
this protease is important for mono-ubiquitin recycling in vivo. We found that this is not the case 
in Drosophila. 
 Prior work conducted on DmUSP5 delivered some information on its role on mono-
ubiquitin levels. One study (Wang et al., 2014) found either increased levels or non-depleted 
mono-ubiquitin in DmUSP5 mutants in Drosophila. However, whether this meant that fly USP5 
is dispensable for mono-ubiquitin recycling was not clarified. Another study observed increased 
levels of conjugated ubiquitin, while the levels of mono-ubiquitin did not appear to be 
consistently depleted when the gene was mutated in the fruit fly (Kovacs et al., 2015). Both of 
these studies arrived at a similar conclusion: USP5 is important for ubiquitin homeostasis in 
Drosophila. The issue raised in our present work, whether USP5 is needed for mono-ub 
recycling in Drosophila, required further investigation. 
 We presented evidence that Drosophila USP5, which functions similarly to its human 
counterpart in vitro, is required during fly development but seems dispensable in adults. These 
findings correspond well with previously published reports by others and us, which showed that 
this DUB is required in developing flies:  ubiquitous knockdown and knockdown in select tissues 
(e.g. neurons and glial cells) during development has negative effects (Tsou et al., 2012; Wang et 
al., 2014; Kovacs et al., 2015).  
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 In reconstituted systems, both human and fly USP5 efficiently cleave ubiquitin chains 
linked head-to-tail and through K11, K48 and K63. K11- and K48-linked ubiquitin have been 
connected to the degradation of proteins by the proteasome, while K63-linked chains have been 
associated with other pathways, including DNA repair, endosomal recycling and autophagy 
(Ikeda and Dikic, 2008; Nathan et al., 2013). Our in vitro data also hint at the possibility that 
USP5 may have specific substrates. This DUB was able to rapidly and efficiently deubiquitinate 
at least one recombinant, ubiquitinated protein in a reconstituted system, but not a second. There 
have been other reports of mammalian USP5 acting on specific substrates in vitro and in vivo 
(Scaglione et al., 2011; Garcia-Caballero et al., 2014). 
 While we found a clear importance for the presence of this DUB during larval and pupal 
stages, USP5 did not seem important when it was knocked down only during adult stages, even 
though it is well expressed in adults, based on transcriptional data aggregated on Flybase.org. If 
DmUSP5 is acting on specific substrates, perhaps they are not as critical in adults as in earlier 
stages. Alternatively, expression of other DUBs may at this point complement some of the USP5 
functions that they could not in larval and pupal stages. We hope to identify specific DmUSP5 
substrates in the near future through quantitative mass spectrometry. 
 Our collective genetic and biochemical experiments indicate that the function of 
DmUSP5 in flies is not to maintain mono-ubiquitin. Perhaps it is useful to compare our results 
with data from work conducted with another DUB, USP14, which is important for maintaining 
mono-ubiquitin in the nervous system of mice (Anderson et al., 2005; Crimmins et al., 2006; 
Chen et al., 2009; Chen et al., 2011; Hallengren et al., 2013). Mutations in USP14 lead to 
reduced mono-ubiquitin protein levels and increased transcription of ubiquitin-encoding genes 
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(Chen et al., 2011). Importantly, introduction of wild type mono-ubiquitin alleviates some of the 
phenotypes caused by loss of USP14 (Chen et al., 2011). In our case, depletion of DmUSP5 does 
not lead to lower levels of mono-ubiquitin (in fact, we see a trend of increased mono-ubiquitin at 
the protein level), transcription of fly ubiquitin-encoding genes is not increased, and introduction 
of exogenous ubiquitin does not suppress the lethality effect of DmUSP5 knockdown. Thus, our 
work argues that DmUSP5 is not critically needed to maintain the mono-ubiquitin pool in vivo in 
Drosophila. 
 qRT-PCR results hint that maintenance of mono-ubiquitin when DmUSP5 is knocked 
down may result from increased transcription of other DUBs that can yield mono-ubiquitin, such 
as USP14. Other investigators also described increased levels of various DUBs when DmUSP5 
was knocked down or absent in the fly (Wang et al., 2014; Kovacs et al., 2015). Upregulation of 
these other DUBs, however, appears unable to suppress lethality caused by DmUSP5 knockdown 
or to normalize the levels of conjugated ubiquitin species that we observe in western blots. These 
findings suggest a highly regulated and flexible system for DUB expression in vivo, while also 
underscoring the non-redundant roles that these proteases play in intact organisms, as we also 
described before (Tsou et al., 2012).  
 Excess conjugated ubiquitin may hinder ubiquitin-dependent proteasomal degradation of 
proteins by competing for binding to the 19S proteasome. Based on our work with the reporter 
CL1-GFP and the endogenous proteins cyclin A, Sin3 and VCP/p97, proteasome function is 
indeed reduced when DmUSP5 is knocked down throughout the fly.  
 Our work leads us to propose that a primary function of DmUSP5 in Drosophila is the 
disassembly of conjugated ubiquitin, which helps, at least in part, to maintain proteasome 
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activity. When this protease is unavailable, increased transcription of other DUBs could assist 
with the processing of some conjugated ubiquitin to recycle mono-ubiquitin. However, these 
proteases appear unable to fully complement DmUSP5 activities. We suggest that as the 
proteasome is inhibited by species that would have been disassembled by DmUSP5, conjugated 
and mono-ubiquitin levels increase as ubiquitinated substrates and ubiquitin (itself a proteasome 
substrate, (Shabek and Ciechanover, 2010)) are degraded less rapidly. Ultimately death ensues, 
probably due to proteasomal inhibition. 
 In summary, we presented evidence that DmUSP5 is not required for mono-ubiquitin 
maintenance in vivo. Based on our additional work that DmUSP5 has wide, although not 
universal, ubiquitin chain linkage preferences, it will be of interest to continue to examine the 
various pathways and processes in which this developmentally required DUB is involved. In the 
next chapter, we move on to the second DUB starring in this thesis, ataxin-3. 
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Table 2.1 DUB Primers for qRT PCR
 
 
USP5 is not needed to maintain mono-ubiquitin 
Table 1 - Drosophila Lines 
able 2 - qRT-PCR Primers Used 
Stocks Source ID Description 
w[1118]; P{GD6741}v17567 VDRC 17567 DmUSP5 UAS-RNAi-1
w[1118]; P{GD6741}v17568 VDRC 17568 DmUSP5 UAS-RNAi-2
y[1] v[1]; P{TRiP.JF02163}attP2 BDSC 31886 DmUSP5 UAS-RNAi-3
y[1] v[1]; P{y[+t7.7]=CaryP}attP2 BDSC 36303 Host strain for RNAi-3
w[1118] VDRC 60000 Host strain for RNAi-1, -2
w[*]; UAS-HA-Uiquitin BDSC 32055 Expresses HA-tagged ubiquitin under UAS control
w[*]; tubP-Gal80ts BDSC 7018
Temperature sensitive Gal80 
that is expressed under the 
control of the alphaTub84B 
promoter
 w[*]; UAS-CL1-GFP Dr. Udai Pandey
GFP with CL1 degron, 
reporter of ubiquitin-
dependent proteasome 
activity, under UAS control
w[*]; sqh-Gal4 Dr. Daniel Eberl Ubiquitous driver
w[*]; actin-Gal4 Dr. Daniel Eberl Ubiquitous driver
w[*]; da-Gal4 Dr. R. J.  Wessells Ubiquitous driver
Target Forward Primer  5’-3’ Reverse Primer 5’-3’
rp49 AGATCGTGAAGAAGCGCACCAAG CACCAGGAACTTCTTGAATCCGG 
bap1/
calypso
CAACAACAGTCTCAGCCACAAT GACGAATATCTCAGCAGTTGTCTC 
rpn11 CTCAATCGCCACTACTACTCGAT CATAACCTTGTCCACCTTCTCCT 
uch GTGCCGGTAATTGTGTGTAGAA GAATCCATTCCAAGGTGTCATC 
uch-l5/
uchl3
ACGGTGCTGGAAATTGGTGTCTCATTG AAGAAGATGTTCTCCCGATCCAG 
usp1 ACCTTGCGCTGCTACAGTCTAC GCTCTTGAGCCTCTTCAATTCT 
usp5 GTACGAGATCAAGGACACGTACAG GTCAGATTAAGCCAGAGGTTGTTG 
usp8 GCATTACAAGTCACCAACACCTTC CCAGATTCTTCAGTCCAGTCAGT 
usp14 ACTCCTGTCAAATTCATTGAGGAC CAAATATAGACTTCATGGCAGACG 
usp32 TTGATCTGTTCTACGGCCAGTT AGTACTTGCAATCGGAGTTCAGAC 
usp20-33 CTTGTGGAGTACATAGCAGAGCAG CTGCTGCTGAAGTGACTGGTATT
usp47 ACGTATTCCCATCAAAATTCTGTC TCGCTGATCTGTGATAATGAAAGT 
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 at W
ayne State University Libraries on June 20, 2017
http://www.jbc.org/
Downloaded from 
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CG2960 CACACTCTCTTTTCCCTTTTTCTTT GTGGACTCCTTCTGAATGTTGTAGT
CG5271 CGCACCCTCTCTGACTATAACATT CCGTTCTCGTCAACCTTGTAGTAT
CG32744 GGACGTCCGAGCAAGTAAAA ATGGCTCAACCTCCAAAGTG
CG11624 CTTCGTCTCCGTGGTGGTAT AGGGTGGACTCCTTCTGGAT
CL1-GFP ACGTAAACGGCCACAAGTTC AAGTCGTGCTGCTTCATGTG
Alternative DmUSP5 primers used, with similar results:
usp5 GGCGGCCAAATACGTAAATA CGTCCTTGTAGATGGGAGGA
usp5 CTCCGCACCTGGATAAGAAG CGGTCAGATTAAGCCAGAGG
usp5 TCGGATGTGTTCTCCTACCC CCATCGACTTCTCGCTCTTC
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CHAPTER 3: VCP MODULATES ATAXIN-3’S AGGREGATION AND TOXICITY IN A 
DROSOPHILA MODEL OF SPINOCEREBELLAR ATAXIA TYPE-3
Chapter 2 highlighted the physiological importance of USP5 in Drosophila, in this chapter we 
switch gears to ataxin-3. 
3.1 Introduction 
 Spinocerebellar Ataxia Type-3 (SCA3, or Machado Joseph Disease) is an age-related, 
neurodegenerative disease that is the most common, dominantly inherited ataxia in the world. 
SCA3 belongs to the family of polyglutamine (polyQ) diseases along with six other SCAs (1, 2 , 
6, 7 and 17), Huntington’s Disease, Spinal and Bulbar Muscular Atrophy and 
Dentatorubropallidoluysian Atrophy (Todi et al., 2007; Zoghbi and Orr, 2009; Costa Mdo and 
Paulson, 2012). These diseases are characterized by abnormally expanded CAG triplet repeats in 
the respective genes, which leads to expanded polyQ tracts in their proteins. Expanded polyQ 
repeats in these proteins cause their misfolding and the formation of insoluble aggregates (Todi 
et al., 2007; Zoghbi and Orr, 2009; Costa Mdo and Paulson, 2012). SCA3 is caused by an 
expansion of the CAG repeat of the ATNX3 gene which encodes the protein ataxin-3 (figure 
3.1A). There is no cure for SCA3; only minimally effective symptomatic therapies exist in the 
clinic (Costa Mdo and Paulson, 2012).  
 Ataxin-3 is a deubiquitinating enzyme that has been linked to protein quality control with 
various partners. One such partner is Valosin Containing Protein (VCP, also known as p97), a 
member of the AAA ATPase (ATPases associated with diverse cellular activities) family of 
proteins (Meyer et al., 2012). VCP contains two tandem ATPase domains, D1 and D2, an N-
terminal domain which is responsible for binding to most of its co-factors and a short C-terminal 
tail (figure 3.1) (Xia et al., 2016). It functions as a homohexamer, converting chemical energy 
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harvested from ATP hydrolysis to 
mechanical energy to exert force on 
its substrates. It is an essential, 
ubiquitously expressed protein in 
mammalian cells. It is localized 
mainly in the cytoplasm of the cell but 
also exists in the nucleus to a lesser 
extent (Madeo et al., 1998; Xia et al., 
2016). VCP is involved in numerous 
cellular processes including protein 
degradation (Dai et al., 1998; 
Buchberger et al., 2010; Meyer et al., 
2012; Kim et al., 2013; Xia et al., 
2016). Ataxin-3 and VCP have been implicated in endoplasmic reticulum associated degradation 
(ERAD) (Zhong and Pittman, 2006; Morreale et al., 2009). 
 The Drosophila homolog of VCP, Ter49, modulates toxicity caused by polyQ expansion 
in generic polyQ models in the fly. Higashiyama et. al. reported that higher levels of VCP 
exacerbates toxicity in fly eyes, whereas loss of function mutations improved degeneration 
caused by an isolated polyQ repeat (Higashiyama et al., 2002). Several reports demonstrated that 
ataxin-3 and VCP interact; one study mapped this interaction to the C-terminus of the DUB, 
preceding the polyQ repeat (figure 3.1) (Hirabayashi et al., 2001; Boeddrich et al., 2006; Fujita 
et al., 2013). According to biochemical and cell-based experiments, ataxin-3 binds to the N -
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Figure 3.1: Ataxin-3 and VCP. 
Note: Diagrams are not to scale 
A. Diagram of ataxin-3 protein. The catalytic domain, 
Josephin Domain, is located at the structured N-terminus 
half of the protein. The inherently unstructured C-terminus 
portion contains three Ubiquitin Interacting Motifs (UIMS), 
the polyQ tract (which is abnormally expanded in SCA3 
patients) and the VBM (green). Box showing VBM was 
mutated from RKRR to HNHH to disrupt the interaction with 
VCP. 
B. Diagram of VCP. VCP functions as a homohexamer, 
Each VCP protein is made of an N-terminal domain, 
through which it binds to most of its co-factors, two tandem 
ATPase domains (D1 and D2) and a short C-terminal tail.
 60
terminal portion of VCP through an arginine-rich area (amino acid sequence RKRR) (Boeddrich 
et al., 2006). Mutating the VBM (VCP-binding motif) on ataxin-3 disrupts the interaction 
between these two proteins (Boeddrich et al., 2006). The same group also showed that VCP 
stimulates fibrillogenesis of non-pathogenic, wild type ataxin-3 in a dose dependent manner in in 
vitro, reconstituted systems (Boeddrich et al., 2006). Mutating the VBM on pathogenic ataxin-3 
in Drosophila also decreased degeneration caused by this protein in fly eyes. However, it was not 
clear from the earlier studies whether VCP regulates the aggregative propensity of pathogenic 
ataxin-3 in vivo; also, the relation of this direct interaction to the temporal aggregation and 
pathogenicity of ataxin-3 in an intact animal was not studied. Here, we set out to understand, by 
using Drosophila as a model organism, the importance of the ataxin-3-VCP interaction in the 
aggregation and pathogenicity of the SCA3 protein, with the hope of elucidating the targetability 
of this binding site for SCA3 therapeutics. Toward this end, we generated new, isogenic lines of 
Drosophila melanogaster that express in a Gal4-UAS-dependent manner (Brand and Perrimon, 
1993; Brand et al., 1994; Sutton et al., 2017) full-length pathogenic ataxin-3 with a normal or 
mutated VBM. We found that pathogenic ataxin-3 with a mutated VBM is markedly less toxic in 
vivo in flies, even though the protein is abundantly present. Initially, flies that express the SCA3 
protein with a mutated VBM are indistinguishable from controls that do not express ataxin-3. 
This coincides with lower levels of aggregated ataxin-3 species. With age, flies that express 
ataxin-3 with a mutated VBM also develop structural and physiological phenotypes, but with a 
timeline markedly slower than flies that express the intact, pathogenic variant of this protein. 
Altering the levels of endogenous VCP protein modulates the toxicity of the SCA3 protein in a 
manner that indicates a nucleation role for the aggregation of ataxin-3 by this AAA ATPase. 
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Collectively, our data highlight an important physiological role for VCP on ataxin-3-dependent 
toxicity, and implicate this interaction as a valuable target for SCA3 therapeutics. 
3.2 Materials and Methods  
Drosophila lines: Husbandry was conducted at 25˚C on standard cornmeal food at 40-60% 
humidity in regulated diurnal environments. SCA3 flies expressing pathogenic ataxin-3 with 
77-80 polyQ repeats were previously generated by cloning into the pWalium10-moe vector 
(Sutton 2017). HNHH mutations were generated on the ataxin-3 backbone using the QuikChange 
mutagenesis kit (Aglient) and used to create HNHH pathogenic ataxin-3 encoding flies using this 
construct cloned into pWalium10-moe vector. Injections (Duke University Model System) were 
into y,w;+;attP2. Common fly stocks were procured from the Bloomington Drosophila Stock 
Center; isogenic host strain attP2 (#36303), VCP RNAi lines were stocks (#32869, #35608). 
Western blotting: Five whole flies or 15 dissected heads per group were homogenized in hot 
lysis buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM dithiothreitol), sonicated, 
boiled for 10 minutes, and centrifuged at top speed at room temperature for 10 minutes. Western 
blots were developed using charge-coupled device-equipped VersaDoc 5000MP system 
(BioRad). Blots were quantified using Quantity One software (BioRad). For direct blue staining 
PVDF membranes were submerged for 5 min in 0.1%Direct Blue 71 (Sigma-Aldrich) stock 
solution in ultra pure water, dissolved in 40% ethanol and 10% acetic acid solvent. Membrane 
was rinsed briefly in solvent, then ultra pure water, air dried and imaged.  
Nuclear Cytoplasmic extraction: Experiments were conducted using the ReadyPrep Protein 
Extraction Kit (Cytoplasmic/Nuclear) (BioRad) to enrich cytoplasmic and nuclear proteins. 5 
whole flies were lysed in cytoplasmic extraction buffer ((CPEB), BioRad).  Nuclei were 
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resuspended in Protein Solubilization Buffer ((PSB), BioRad). Samples were run on 4-20% 
gradient gel (BioRad) and analyzed by western blot.  
Antibodies: Anti-Ataxin-3 monoclonal (clone 1H9, mouse, 1:500-1000; Milipore), anti-tubulin 
(mouse  monoclonal T5168, 1:10,000; Sigma-Aldrich), anti-VCP (valosin-containing protein; 
rabbit monoclonal,1:1000, Cell Signalling Technology), anti-lamin (ADL84.12-5 mouse 
monoclonal, 1:1000, Developmental Studies Hybridoma Bank), peroxidase conjugated 
secondary antibodies (goat anti-mouse and goat anti-rabbit, 1:5,000; Jackson Immunoresearch) 
Motility Assay (Negative Geotaxis): Motility was tested once a week for a total of four weeks. 
10 flies per vial were forced to bottom of vial by light tapping on the bench. The number of flies 
that reached that top of the vial at 5, 15 and 30s was recorded. Flies were transferred to new vial 
1h before assessment, and every 2-3 days for duration of the experiment.   
Longevity Assay: Approximately 25 flies per vial were collected after eclosion from the pupal 
case and aged on conventional cornmeal fly media or RU-486 containing media at 25°. Flies 
were switched to vials with fresh food every 2-3 days. Each vial was checked for death daily, 
until all flies were dead.  
Histology: Fly proboscises and wings were removed before fixing over night in 2% 
gluteraldehyde/2% paraformaldehyde in Tris-buffered saline with 0.1% Triton X-100. Fixed flies 
were dehydrated  in series of 30, 50, 70, 100% ethanol washes and washed in propylene dioxide 
over night. Whole fly bodies were embedded in Poly/Bed812 (polysciences), sectioned at 5µm 
and stained with toluidine blue. 
Quantitative PCR: Total RNA was extracted from larvae using TRIzol (Life Technologies). 
Extracted RNA was treated with TURBO DNAse (Ambion). Reverse transcription was carried 
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out using the high capacity cDNA reverse transcription kit (ABI). mRNA levels were quantified 
using the StepOne Real-Time PCR system with Fast SYBR Green Master Mix (ABI). 
Primers: 
SCA3  F: 5’-GAATGGCAGAAGGAGGAGTTACTA- 3’ 
SCA3 R: 5’-GACCCGTCAAGAGAGAATTCAAGT- 3’ 
rp49 F: 5’ -AGATCGTGAAGAAGCGCACCAAG- 3’ 
rp49 R: 5’ -CACCAGGAACTTCTTGAATCCGG- 3’ 
Co-Immunoprecipitation: 30-50 fly heads per group were homogenized through mechanical 
disruption in PBS+PI, briefly sonicated and then supplemented with the equal volume of NETN
+PI. Lysates were vortexed briefly every 5 minutes for a total of 30 minutes, centrifuged at 5,000 
X g for 5 minutes and supernatant was transferred to 30 µL slurry of anti-HA bead-bound 
antibody (Sigma-Aldrich). Beads with lysates were tumbled at 4˚C for 4 hours, rinsed thrice with 
NETN+PI, and bead-bound complexes were eluted with heat and Laemmli buffer. 
3.3 Results 
3.3.1 Mutating the VBM of ataxin-3 does not alter its protein or mRNA levels, or its 
subcellular localization 
 To begin studying the role that the interaction of ataxin-3 and VCP plays in the 
pathogenesis of the polyQ disease Spinocerebellar Ataxia Type-3 (SCA3), we created new 
transgenic Drosophila lines expressing ataxin-3 with 80 polyQ repeats, which is within the 
pathogenic range of SCA3. The lines were made by cloning this ataxin-3 transgene into the 
pWalium10-moe vector, which was used with the phiC31 site-specific integrase system to insert 
the construct at the attP2 site on the third chromosome of the fly (Groth et al., 2004; Markstein et 
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al., 2008; Tsou et al., 2016) (figure 3.2). These flies are referred to as ‘Intact ataxin-3' in our 
studies. Boeddrich et. al. previously showed that ataxin-3 and VCP directly bind through the 
VBM domain on ataxin-3 and that mutating the VBM from RKRR to HNHH disrupts the 
interaction between ataxin-3 and VCP (Boeddrich et al., 2006). We created another transgenic fly 
line which encodes the same pathogenic ataxin-3 construct  inserted at the same site on 
chromosome 3 of the fly, but in which the VBM on ataxin-3 was mutated from RKRR to HNHH 
(HNHH fly line) by site-specific mutagenesis. These flies are referred to as HNHH 1 and 2, as 
we utilized two independently derived lines.  
 Before beginning our studies, we wanted to confirm that any difference in phenotype we 
observe among the different lines is due to the disrupted interaction between ataxin-3 and VCP 
and not because of a change in ataxin-3 expression levels. We examined mRNA expression 
levels of ataxin-3 by qRT-PCR 
when the protein was expressed in 
the whole fly using the ubiquitous 
driver sqh-Gal4 (figure 3.3A). 
The HNHH-1 and -2 lines were 
compared to the line encoding 
pathogenic ataxin-3 with an intact 
VBM. We found that there was no 
statistically significant difference 
in the expression levels of 
ataxin-3 among the three fly lines. 
!  
Figure 3.2: Cloning.  
Pathogenic ataxin-3 was cloned into pWalium10. PhiC31 
integrase was used to insert pathogenic ataxin-3 at the attP2 
site on the third chromosome of Drosophila.
!  
Figure 3.2: Cloning  
Pathogenic ataxin-3 was cloned into pWalium10 vector. i  integrase 
was used to insert pathogenic ataxin-3 at the attP2 site on t  third 
chromosome of Drosophila.
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Our lab also previously showed that ataxin-3 turnover was not affected when the VBM was 
mutated from RKRR to AAAA in  HEK cells (Blount et al., 2014).  
 To make sure that mutating the VBM of ataxin-3 disrupts its interaction with VCP in vivo 
in Drosophila we carried out co-immunoprecipitation experiments (figure 3.3C). We 
exogenously expressed HA-tagged VCP in fly eyes along with intact pathogenic ataxin-3 or 
pathogenic ataxin-3 with a mutated VBM using the eye-specific GMR-Gal4 driver. Western blot 
analysis shows that when the VBM is mutated from RKRR to HNHH, pathogenic ataxin-3 does 
not co-precipitate with VCP as shown in figure 3.3C.     
 The VCP binding site on ataxin-3 is an arginine rich region located at the C-terminal of 
ataxin-3. Previously, this domain was thought to act as a nuclear localization signal (Albrecht et 
al., 2004). It has also been shown that ataxin-3 is able to shuttle between the cytoplasm and the 
nucleus, but when it contains the expanded polyQ tract it preferentially localizes in the nucleus, 
where it is highly toxic (Costa Mdo and Paulson, 2012). We examined whether mutating the 
VBM would affect the localization of pathogenic ataxin-3 in the fly by using a fractionation kit 
to enrich cytoplasmic and nuclear proteins from whole fly lysates when pathogenic ataxin-3 
expression is driven by the ubiquitous driver sqh-Gal4. After analysis by western blotting and 
probing with ataxin-3 antibody, we observed no difference in protein distribution between the 
cytoplasm and nucleus when the VBM is mutated (figure 3.3B). We conclude that mutating the 
VBM from RKRR to HNHH does not impact the cellular localization of pathogenic ataxin-3 in 
the fly. These results indicate that any phenotype that we observe is not due to less or more 
ataxin-3 in the nucleus, and is more likely an effect of the interaction of ataxin-3 with VCP.  
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3.3.2 Mutating the VBM of ataxin-3 reduces its toxicity in Drosophila when expressed in all 
tissues and delays accumulation of SDS-resistant species 
  To physiologically assess how a VBM mutation affects the toxicity of ataxin-3 in 
Drosophila, we conducted longevity studies. As previously shown by our group (Sutton et al., 
2017), pathogenic ataxin-3 is highly toxic to the fly when it is expressed ubiquitously with sqh-
Gal4 driver (Sutton et al., 2017). We observed death during late pharate adult stages and during 
eclosure from the pupal case, as well as shortly following eclosion. Those flies that did eclose 
!  
Figure 3.3: Mutating the VBM does not affect expression or localization of pathogenic ataxin-3. 
A. qRT-PCR results from larvae expressing intact pathogenic ataxin-3 or pathogenic ataxin-3 with 
mutated VBM driven by the sqh-Gal4 ubiquitous driver. No significant differences in the mRNA 
expression levels when the VBM is mutated to HNHH. Means ± SD. N=4. P values were calculated by 
Student’s t-tests. Flies were heterozygous for driver and transgene. 
B. Western blot of fly lysates after cytoplasmic/nuclear protein fractionation. Cytoplasmic and nuclear 
fractions from flies expressing intact pathogenic ataxin-3 or HNHH pathogenic ataxin-3 were 
electrophoresed on 4-20% poly-acrylamide gels. Intact control flies were pathogenic ataxin-3 encoding 
flies without a driver. Flies were heterozygous for driver and transgene. Shown is representative 
experiment performed at least thrice from independent biological repeats. 
C. Western blot of co-immunoprecipitation experiment. Input and elutions from different conditions were 
run on 4-20% poly-acrylamide gels. All flies were heterozygous for driver and transgenes. 
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successfully survived for about 29 days (figure 3.4A). HNHH mutant flies all reached adulthood. 
We did not observe any death during development as we had with flies encoding ataxin-3 with 
the intact VBM. Interestingly, even with the reduction in toxicity in early life, in the end these 
flies did not live much longer. From longevity curves, we saw a clear separation in the rates of 
death early on: the HNHH mutants appeared healthier and more flies remained alive in the 
earlier days of life than their intact ataxin-3 expressing counterparts (figure 3.4A). We observed 
that about 50% of flies expressing intact pathogenic ataxin-3 die by day 11 as compared to 
HNHH mutant expressing flies which reached 50% death around day 21. When compared with 
the control flies that do not express pathogenic ataxin-3, both intact VBM containing flies as well 
as those with the mutated VBM domain live a lifespan that is greatly shortened (figure 3.4A). 
Control flies in this experiment contain the sqh-Gal4 driver as well as the cloning vector we used 
(pWalium10-moe) also inserted at the attP2 site, but without an ataxin-3 transgene in it. 
 We assessed by western blotting the expression levels of ataxin-3 protein with one day 
old whole fly lysates where pathogenic ataxin-3 with an intact VBM or pathogenic ataxin-3 with 
a mutated VBM were expressed in the whole fly using the ubiquitous driver, sqh-Gal4. Our 
results show that flies which harbor pathogenic ataxin-3 with an intact VBM have an 
accumulation of higher molecular species, indicative of ataxin-3 SDS-resistant aggregates as 
early as day one after eclosion, whereas flies with a mutated VBM do not have this high 
molecular smear rather: they show more soluble ataxin-3 (figure 3.4B).  
 As already noted, SCA3 is an age-related, progressive neurodegenerative disease. While 
aging the flies in the longevity experiment, we collected flies for western blot analysis at day one 
after eclosion, day 7 and day 14 to examine the state of SDS-resistant species as flies age and to 
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Figure 3.4: Mutating the VBM of ataxin-3 delays its aggregation and toxicity. 
A. Longevity assay. Flies were collected immediately after eclosing from the pupal case and aged until 
death. Vials were monitored for death on a daily basis. Control flies contain the ubiquitous, sqh-Gal4 
driver and cloning vector (pWalium10-moe) inserted at the attP2 site, but without an ataxin-3 transgene. 
Control flies lived up to 90 days.  
B. Western blots of one day old fly lysates, electrophoresed on 4-20% poly-acrylamide gels, when 
ataxin-3 transgenes were driven by the ubiquitous, sqh-Gal4 driver. Flies were heterozygous for driver 
and transgene. Blot shown is representative of experiment done three times from independent 
biological repeats. 
C. Timeline of aggregate accumulation. Fly lysates collected on noted dates after eclosure. Pathogenic 
ataxin-3 protein transgenes were expressed in whole fly by the ubiquitous, sqh-Gal4 driver. Flies were 
heterozygous for all constructs. Representative blot of at least three independent biological repeats.  
✻ ub-ataxin-3. 
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correlate shortened lifespan with ataxin-3 aggregates (figure 3.4C). We observed that at day one, 
SDS-resistant aggregates are already present in flies which expressed the intact pathogenic 
protein, whereas with HNHH mutant flies we only begin to see accumulation of insoluble protein 
species at day 7, and increasing accumulation with age. It is also worth noting that HNHH 
mutants show higher levels of SDS-soluble ataxin-3 as compared to intact counterparts. These 
levels are concomitantly reduced as SDS-resistant species accumulate. Interestingly, we observe 
that the accumulation of high molecular species occurred at a point which preceded death in 
HNHH flies, which suggests a temporal relationship between the accumulating protein 
aggregates and ensuing death in flies exists.  
 Collectively, the above experiments show that mutation of the VBM of ataxin-3 does not 
affect its mRNA or protein expression levels, or the cellular localization of the protein when the 
protein is expressed in the whole fly. When the VBM is mutated, there is a delay in the 
accumulation of SDS-resistant protein species in flies as compared to their intact pathogenic 
ataxin-3 expressing counterparts. Ultimately, disrupting the interaction between pathogenic 
ataxin-3 and VCP does not prolong the life span of flies, but initial toxicity is markedly 
decreased (figure 3.4A), as shown by the separation in longevity chart.   
3.3.3 Ataxin-3 with a mutated VBM is less toxic in the nervous system than the intact 
pathogenic protein  
 Ataxin-3 protein is expressed throughout all tissues and cells in the human body. 
However, the polyQ disease SCA3 manifests as a neurodegenerative disorder with degeneration 
specifically in the brain, affecting the brainstem and the cerebellum (Costa Mdo and Paulson, 
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2012). With the power of fly genetics, we are able to restrict the expression of ataxin-3 only to 
the nervous system using a neuronal-specific driver, elav-Gal4, and examine its effects in the fly.  
 Western blot analysis from whole one day old fly lysates where pathogenic ataxin-3 with 
an intact VBM is expressed pan-neuronally already show accumulation of SDS-resistant ataxin-3 
species (figure 3.5A). Comparing the HNHH, VBM-mutant flies to those flies expressing the 
intact pathogenic protein, the high molecular smear is largely absent with greater presence of 
lower molecular weight, SDS-soluble ataxin-3 species. The control flies used in this experiment 
were flies which contain an intact pathogenic ataxin-3 without the pan-neuronal driver, and thus, 
there was no ataxin-3 expression in these flies.  
 We next aged flies to investigate how ataxin-3 expression in the nervous system affects 
their life span. We observed that the lifespan of flies expressing either intact pathogenic ataxin-3 
or the HNHH mutant counterpart was shortened as compared to control flies which encode and 
express the empty vector control. Control flies live up to 90 days (figure 3.5B). When we 
compare the lifespan of flies expressing pathogenic ataxin-3 with a mutated VBM to those 
expressing the intact pathogenic protein, a higher percentage of flies remain alive initially; that 
is, we observe a 50% reduction of flies expressing ataxin-3 with an intact VBM by day 25 
whereas this reduction occurs around day 35 in flies expressing pathogenic ataxin-3 with a 
mutated VBM. However, even though in earlier time points more HNHH mutant flies remain 
alive, both fly lines have an average life span of 40 to 45 days (figure 3.5B). Flies expressing 
either variant of pathogenic ataxin-3 pan-neuronally live longer than those expressing the same 
constructs ubiquitously with the sqh-Gal4 driver. Ataxin-3 is ubiquitously expressed in all tissues 
in the human body but toxicity manifests specifically in the nervous system. The difference in 
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toxicity observed in this case may be due to expression in all tissues of the fly as compared to 
only in nervous system cells because this excludes glial cells. 
$  
Figure 3.5: A mutated VBM on pathogenic ataxin-3 decreases its toxicity in the nervous system 
of Drosophila. 
A. Mutating the VBM of ataxin-3 delays the accumulation of ataxin-3 protein aggregates. Western blots 
of one day old flies when intact or mutated pathogenic ataxin-3 is expressed in the nervous system with 
the pan-neuronal elav-Gal4 driver. Lysates were electrophoresed on 4-20% poly-acrylamide gel and 
probed using ataxin-3 antibody. Intact control flies encoded pathogenic ataxin-3 protein without driver. 
Flies were heterozygous for driver and transgene. Representative of at least independent biological 
repeats . * nonspecific band. 
B. Longevity assay for Drosophila expressing intact pathogenic ataxin-3 or VBM mutated ataxin-3 in the 
nervous system. Control flies contained empty vector without a transgene inserted at attP2, in the 
presence of elav-Gal4 driver. Control flies live up to 90 days. Flies were heterozygous for driver and 
transgene. 
C. Western blot of aged flies expressing intact or mutated pathogenic ataxin-3 in the nervous system. 
Lysates were prepared from 5 flies each at the indicated time points. Flies are heterozygous for all 
transgenes. Representative of at least three independent biological repeats.Intact control flies encoded 
pathogenic ataxin-3 protein without driver.  * nonspecific band.
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 To investigate the relationship between fly lifespan and the presence of SDS-resistant 
species in the pan-neuronal expression model, we examined by western blotting whole fly lysates 
at five different time points, day 1 to day twenty eight (figure 3.5C). As previously shown, 
(figure 3.5A), presence of SDS-resistant pathogenic ataxin-3 species is evident at day one in 
flies expressing the protein with an intact VBM. Conversely in those flies expressing pathogenic 
ataxin-3 with a mutated VBM high molecular species smear are not prominent until day 14 
(figure 3.5C). In both cases, though, accumulation of high molecular species precedes the point 
at which death is observed in the longevity studies (figure 3.5.B, figure 3.5C). 
3.3.4 Mutating the VBM of ataxin-3 reduces its toxic effect on fly motility 
 SCA3 is a movement disorder, marked by progressive ataxia followed by death. We 
wanted to test the neuronal function of flies when the pathogenic ataxin-3 proteins were 
expressed specifically in the nervous system. Motility is assessed by measuring how many flies 
reach the top of the vial in 5, 15 and 30 seconds. The flies were kept over a period of four weeks 
and motility was assessed weekly (figure 3.6). As early as day seven, flies expressing the intact 
pathogenic protein were slower than control flies containing the empty vector across all three 
time points. This difference increased markedly with age, and at four weeks of age the majority 
of flies did not reach the top of the vial even during the longest time interval, 30 seconds (figure 
3.6, blue bars). Conversely, flies expressing pathogenic ataxin-3 with the mutated VBM 
performed as well as control counterparts for up to three weeks of age. At four weeks of age, 
these flies are slower than empty vector control counterparts but perform markedly better than 
flies expressing intact pathogenic ataxin-3  (figure 3.6, green bars).  
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 In conclusion, expression of intact pathogenic ataxin-3 and HNHH mutant pathogenic 
ataxin-3 pan-neuronally is less toxic than ubiquitous expression in the fly (figure 3.4). When the 
VBM of ataxin-3 is mutated, aggregate accumulation in the fly is delayed as was observed with 
ubiquitous expression of the respective proteins. Furthermore, flies expressing pathogenic 
ataxin-3 with a mutated VBM perform significantly better than their intact pathogenic ataxin-3 
expressing counterparts in the negative geotaxis motility assay, comparable to control flies 
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Figure 3.6: Flies expressing pathogenic ataxin-3 with a mutated VBM perform better in motility 
assays.  
Negative geotaxis assay used to assess motility of flies when the respective proteins are expressed in 
the nervous system with elav-Gal4. The number of flies able to reach the top of the vial in 5, 15 or 30 
seconds was recorded. 10 flies per vial were used in tests. Motility was assessed on a weekly basis. 
Controls in this experiment contain the pan-neuronal, elav-Gal4 driver as well as the cloning vector 
(pWalium10-moe) inserted at attP2 but without the ataxin-3 transgene inserted. Means ± SD. P values 
are from student’s t-Tests. Asterisk; P<0.05. Flies were heterozygous for driver and transgene. 
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expressing empty vector until three weeks of age. We observed that reduced performance by the 
flies expressing pathogenic ataxin-3 with mutated VBM happens on the same day that we first 
observe accumulation of SDS-resistance species by western blotting (figure 3.5B). Flies 
expressing intact pathogenic ataxin-3 have poor performance from the first time point tested 
(week one). These flies already have accumulation of SDS-resistant species as early as day one 
after eclosion (figure 3.5A, figure 3.5B).    
3.3.5 Ataxin-3 with mutated VBM is less toxic in Drosophila eyes 
 Drosophila eyes serve as a widely accepted model to study degeneration in polyQ 
diseases. Histological sections allow visualization of degeneration and accumulation of 
proteinaceous aggregates. Using the eye-specific, GMR-Gal4 driver, we expressed our 
transgenes in the fly eyes and conducted histological assays at different points of the fly life to 
characterize the degeneration caused by expression of pathogenic intact ataxin-3 and what effects 
mutating the VBM has on the phenotype of the eye. The ommatidium is the functional unit of the 
fly eye. Each eye contains approximately 800 ommatidia arranged in a structured array. The 
highly iterative structure of the eye makes it a good model to easily and reliably observe any 
perturbations arising from toxicity (Kumar, 2012).  
 Histological sections from one week old flies showed that there was already some 
disruption of the internal ommatidial array of the eye compared to the control flies which did not 
express any pathogenic ataxin-3 protein (figure 3.7A, panel II compared to panel I). The HNHH 
mutant eyes very closely resembled control eyes, with a well arranged ommatidial array and no 
signs of degeneration (figure 3.7A, panel III and IV). As SCA3 is a progressive disease, we 
expected to observe more degeneration as flies aged over the course of four weeks. This was the 
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case for four week old fly eyes expressing the intact pathogenic ataxin-3 protein, where we saw 
substantial degeneration and loss of structure (figure 3.7B, panel II). We also observed densely 
staining structures, indicative of protein aggregates (Red boxes). In HNHH mutant eyes, we also 
began to observe degradation. However, the ommatidial array was still clearly present and 
remained rather intact over the course of the examinations (figure 3.7B, panel III and IV). In 
summary, from histological sections of the fly eye, we see that mutating the VBM of pathogenic 
ataxin-3 reduces toxicity and preserves normal eye structure. 
 We coupled our histological assays with western blotting from dissected fly heads. 
Western blots from one day old fly heads show that there is already ataxin-3 SDS-resistant 
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Figure 3.7: Disrupting the interaction between ataxin-3 and VCP reduces toxicity in fly eyes. 
(A, B). Histological sections of  fly eyes at one week of age (A) or four weeks (B) when pathogenic 
ataxin-3, intact or HNHH, was expressed in the eyes using GMR-Gal4. Controls in this experiment 
contain the eye-specific, elav-Gal4 driver as well as the cloning vector (pWalium10-moe) inserted at 
attP2 but without the ataxin-3 transgene inserted. 
(C). Western blots of one day old fly head lysates, electrophoresed on 4-20% acrylamide gel.  
Flies are heterozygous for all constructs. Representative of at least three independent biological 
repeats. 
✻ Ub-ataxin-3. Red boxes: example of densely staining structure. 
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species as indicated by the high molecular smears when we probe with ataxin-3 antibody (figure 
3.7C). We do not observe these species when the HNHH mutant pathogenic ataxin-3 is 
expressed in the fly eyes (figure 3.7C). We can draw the conclusion from these results that 
mutating the VBM of pathogenic ataxin-3 delays the formation of aggregates and in turn slows 
the degeneration of fly eyes. Expression of intact pathogenic ataxin-3 causes large degeneration 
of the fly eye within four weeks of age, whereas expression of pathogenic ataxin-3 with a 
mutated VBM showed much less toxicity at the same age.  
 Altogether, the studies conducted in the various tissues with the different forms of 
pathogenic ataxin-3 lead us to conclude that VCP influences the aggregation and toxicity of 
pathogenic ataxin-3, increasing the accumulation of aggregated species and expediting the 
toxicity of this protein in vivo. To further probe into this model, we next turned to endogenous 
VCP in the fly. 
3.3.6 Knockdown of VCP improves degeneration in fly eyes 
 The results we obtained with our earlier experiments indicate that expression of 
pathogenic ataxin-3 protein is less toxic when the VBM is mutated to disrupt interaction with 
VCP. We wanted to confirm that the differences in phenotype we observed were due to the 
interaction, or lack thereof, between ataxin-3 and VCP, by targeting VCP itself. 
 VCP is an essential protein with numerous important functions in the cell; knockdown of 
VCP in the whole fly as well as in the nervous system is developmentally lethal (personal 
communication). However, knockdown of VCP in the fly eyes is tolerated (our lab’s data). Thus, 
we examined whether knockdown of VCP in fly eyes expressing pathogenic ataxin-3 with an 
intact VBM would impact the structure of the eye. 
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 From histological sections at four weeks of age, as previously shown (figure 3.8A), 
expression of intact pathogenic ataxin-3 in the eyes using GMR-Gal4 was toxic and caused the 
breakdown of the ommatidial array (Figure 3.8A, panel 2). We used two different RNAi lines 
targeting VCP, both of which were generated using phiC31 mediated site specific integration and 
were inserted on the third chromosome of the fly at the attP2 (BDSC). As shown in figure 3.8B, 
knockdown of VCP by both RNAi lines led to statistically significant reduction in VCP protein 
levels in the fly head. An important note here is that the blots underestimate the precise level of 
VCP reduction. This is because we target RNAi to the fly eyes, but we examined protein levels 
from intact fly heads. 
 Knockdown of VCP in fly eye led to improvement of pathology caused by ataxin-3. As 
shown in figure 3.8, knocking down VCP with either RNAi-1 or -2 reduced ommatidial disarray 
in the presence of pathogenic ataxin-3 (figure 3.8A). Importantly, concomitant with improved 
pathology we observed reduced levels of SDS-resistant species of ataxin-3 when VCP was 
knocked down. In figure 3.8B, and to a lesser extent in figures 3.4B and C and 3.7C, a higher 
proportion of SDS-soluble ataxin-3 in flies where VCP is knocked down or the VBM of 
pathogenic ataxin-3 is mutated seems to be ubiquitinated. It is possible that when ataxin-3 
proteins bind to VCP they are brought in close proximity and deubiquitinate each other. It is also 
possible that when pathogenic ataxin-3 is ubiquitinated it is less aggregation-prone due to steric 
hindrance. 
 In conclusion, we observe decreased toxicity from ataxin-3 when VCP is knocked down 
in the eyes. Similar to the mutation of VBM on ataxin-3 to disrupt its interaction with VCP, 
decreasing the levels of VCP in the cell suggests that there are less VCP proteins binding 
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Figure 3.8: Knockdown of VCP in fly eyes improves degeneration caused by pathogenic ataxin-3 
expression.  
(A). Histological sections of four week old fly eyes. GMR-Gal4 was used to express pathogenic ataxin-3 
with or without VCP RNAi in the eyes. Vector control contains no ataxin-3 expression. 
✻ ub-ataxin-3  
(B). Western blot of one day old fly head lysates when pathogenic ataxin-3 is expressed alone or with 
VCP RNAi in fly eyes. Right; Quantification of VCP knockdown from four separate experiments. Means 
± SD. Asterisks: P<0.05. P values are from students t-Tests. Flies are heterozygous for all constructs.
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ataxin-3 and bringing them closer together to form aggregates. Collectively, these data support 
our overall model that VCP enhances ataxin-3 aggregation and toxicity. 
3.3.7 Ataxin-3 expression after development  
 Intrigued by our results with the ubiquitous driver, which showed the presence of SDS-
resistant ataxin-3 species before we observed lethality in flies, as early as day one after eclosing 
with expression of intact pathogenic ataxin-3, we wanted to further examine the temporal 
relationship between these SDS-resistant species and death. In our previous experiments, 
expression of pathogenic ataxin-3 proteins (intact and HNHH mutant) was driven throughout 
development and in adults. In the next round of experiments, we harvested the power of fly 
genetics to switch on ataxin-3 expression after adults eclosed and for specific points of time to 
examine the possibility of a correlation between ataxin-3 death and the accumulation of SDS-
resistant ataxin-3 species in neural tissues.  
 We used the tissue specific and inducible GeneSwitch Gal4 driver system (Osterwalder et 
al., 2001; Nicholson et al., 2008). Male fly and virgin female flies are crossed, one encoding an 
ataxin-3 construct and the other a pan-neuronal GeneSwitch, elav-GAL4 driver. The flies are 
crossed on normal fly media, lacking the GeneSwitch activator, RU-486. Once offspring from 
the cross eclosed, we switched them to fly media containing the inducer, RU-486. RU-486 
activates the GeneSwitch protein, which in turn drives the expression of the respective 
pathogenic ataxin-3 transgenes pan-neuronally. The offspring were aged on RU-486-containing 
food and collected for lysates on day one, four, seven, ten, 14, 21, 28 and 35 and further 
examined by western blotting with ataxin-3 antibody for protein aggregation (figure 3.9A, left 
panel).  
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Figure 3.9: Expression of pathogenic ataxin-3 only in adult stages does not prolong lifespan. 
When expression of intact or mutated pathogenic ataxin-3 expression is started after flies eclose from 
the pupal case, life span does not differ from that of flies in which the proteins are expressed throughout 
development as well (figure 3.5).  
(A). Left panel; western blot of fly lysates at indicated ages (days) when pathogenic ataxin-3 is 
expressed in the nervous system by the RU-486-inducible GeneSwitch elav-Gal4 driver. Right panel; 
blots from HNHH mutant pathogenic ataxin-3 expressed pan-neuronally by the inducible driver. Control 
lysate for this experiment was from flies expressing intact pathogenic ataxin-3 or HNHH pathogenic 
ataxin-3 by the constitutive pan-neuronal elav-Gal4 driver at day one (driver that was used in fig. 3.5). 
Bottom blot, samples re-run on the same poly-acrylamide gel. Blots representative of three independent 
biological repeats. Flies are heterozygous for all transgenes. 
(B). Longevity assay for flies expressing intact or mutated pathogenic ataxin-3 by RU496-inducible pan-
neuronal driver. Flies are heterozygous for all constructs.  
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 When intact pathogenic ataxin-3 is driven by the RU-486 inducible elav-Gal4 driver, we 
do not observe SDS-resistant species until day ten, compared to flies in which intact pathogenic 
protein expression is driven by the pan-neuronal driver elav-Gal4, where we observed SDS-
resistant species at day one (Figure 3.9A). Intriguingly, we do not observe a delay in the time of 
death between flies that express the pathogenic, intact ataxin-3 protein throughout development 
and adulthood (elav-Gal4, figure 3.5) and those in which expression of the pathogenic protein is 
started in early adulthood with the GeneSwitch driver (Figure 3.9A). In fact, flies expressing 
pathogenic ataxin-3 by RU-486-inducible elav-Gal4 driver may overall die earlier than their 
counterparts driven by the non-inducible driver (figure 3.9B blue line, compare to figure 3.5B 
blue line). 
 A similar pattern is observed when pathogenic ataxin-3 with a mutated VBM is 
conditionally expressed in flies after they eclose (figure 3.9, right panel). SDS-resistant species 
are evident around day 21 by western blotting. As in experiments shown above (figures 3.4 and 
3.5), mutating the VBM of pathogenic ataxin-3 delays the accumulation of SDS-resistant species 
in Drosophila. We do not observe accumulation of SDS-resistant species with HNHH mutants 
with the inducible or non-inducible drivers used previously at day one. However, the flies in 
which expression of pathogenic ataxin-3 begins during adulthood ultimately die at the same time 
as their counterparts in which the protein is expressed throughout development as well, around 
day 45 of age (Figure 3.9B). We do observe that flies which express pathogenic ataxin-3 with a 
mutated VBM driven by the inducible pan-neuronal driver show 50% death around day 27, 
whereas with the non-inducible elav-Gal4 driver 50% death is not observed until day 35 as noted 
above (figure  3.9B green line, figure 3.5B green line).  
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 Collectively from these experiments, expression of intact pathogenic ataxin-3 or 
pathogenic ataxin-3 with a mutated VBM pan-neuronally in the fly using the RU-486-inducible 
Gal4 driver to express after fly eclosure does not extend lifespan of the flies as compared to 
those flies in which the pathogenic proteins are expressed throughout development. One 
explanation for the similarity in lifespan is that the inducible driver drives higher expression of 
ataxin-3 protein and thus is more toxic to the fly and causes death at a similar time point as in 
flies with ataxin-3 expression all throughout development (figure 3.9B, 3.5B). Similar to our 
other experiments, we also observed that mutating the VBM extends the time it takes for SDS-
resistant species to accumulate in the fly as shown by western blots (figure 3.9A, 3.5C). There is 
about a 10 day delay in the accumulation of SDS-resistant species in flies expressing the mutated 
version of pathogenic ataxin-3 in comparison to flies expressing the intact pathogenic protein 
(figure 3.9A). Another explanation for the similar time of death when pathogenic ataxin-3 is 
expressed conditionally in adult as compared to all throughout development is that developing 
neurons may have better mechanisms to withstand the burden from accumulating SDS-resistant 
species. It could be that degradation systems are not as effective in the terminally differentiated 
neurons, combined with higher pathogenic ataxin-3 expression could explain the earlier 50% 
death, and overall death at the same age. 
3.4 Discussion 
 SCA3 is a devastating, progressive disease with no available cure and poor symptomatic 
therapies. Further studies to better understand ataxin-3 functions, interacting partners and 
mechanisms will be instrumental in designing therapies and hopefully finding a cure for this 
disease. PolyQ disease associated protein aggregation has long been studied at terminal stage, 
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after aggregation has already occurred. We decided to take a different approach and examine the 
factors that are involved in the initial stages of promoting protein aggregation in the disease state. 
Boeddrich et. al. previously showed that ataxin-3 and VCP directly interact through a VBM 
domain on the C-terminal of ataxin-3, and when this domain is mutated, binding between the two 
proteins is disrupted in vitro and in mammalian cells (Boeddrich et al., 2006). Our studies 
showed that disrupting the interaction between ataxin-3 and VCP in a Drosophila model of 
SCA3 delays aggregation of pathogenic ataxin-3 and decreases its toxicity. 
 We showed that expression of pathogenic ataxin-3 with a mutated VBM did not alter 
mRNA expression levels as compared to its intact ataxin-3-expressing counterparts, nor did it 
affect the cellular localization of the protein. When the proteins were expressed ubiquitously or 
pan-neuronally, using the sqh- and elav-Gal4 drivers respectively, the HNHH mutant expressing 
flies did not show accumulation of protein aggregates by western blotting until 14 and 21 days of 
age. Conversely, flies expressing the intact pathogenic protein with the same drivers showed 
accumulation of SDS-resistant species by western blot at day one after adults eclosed from the 
pupal case. This delay we observed in aggregate accumulation may explain the trend that occurs 
in the longevity curves with both ubiquitous and pan-neuronal expression of the ataxin-3 
variants. In both instances we saw that a larger number of HNHH mutant expressing flies remain 
alive initially, whereas those expressing intact pathogenic ataxin-3 started to decline much earlier 
(figure 3.4A, figure 3.5C). Similar to the delay we see in aggregate accumulation, we also 
observe a delay in death when ataxin-3 VBM is mutated. Ultimately, however, there was no 
difference in lifespan between these two fly lines with either driver. Even though mutating the 
VBM leads to a disrupted interaction between pathogenic ataxin-3 and VCP, it cannot ultimately 
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prevent aggregation of ataxin-3 which has an inherent ability to aggregate, whether wild type or 
pathogenic (Masino et al., 2004; Ellisdon et al., 2006).  
 Our studies address the role of VCP in the early stages of ataxin-3 aggregation, which 
seems to bring pathogenic proteins closer together to accelerate their aggregation. VCP may also 
act as a mediator in ataxin-3 aggregation providing more structure to the process, whereas 
without VCP ataxin-3 does not aggregate as rapidly. Accumulation of SDS-resistant species 
occurs faster in flies expressing intact pathogenic ataxin-3 than in flies expressing pathogenic 
ataxin-3 with a mutated VBM (figure 3.4C, figure 3.5C). Flies expressing intact pathogenic 
ataxin-3 reach a toxic threshold of SDS-resistant species earlier than their counterparts 
expressing pathogenic ataxin-3 with a mutated VBM (figure 3.4B, C and figure 3.5A, C). This 
corresponds to the division in longevity curves shown in figures 3.4A and 3.5B, where we begin 
to observe death in intact pathogenic ataxin-3 expressing flies much earlier than in flies 
expressing pathogenic ataxin-3 with a mutated VBM. Once the flies expressing HNHH ataxin-3 
variant reach a threshold of SDS-resistant species, death occurs rapidly. This could also be 
explained by the motility assay where we see the flies that express pathogenic ataxin-3 with a 
mutated VBM perform very similarly to control counterparts without pathogenic ataxin-3 
expression (figure 3.6), but their motility is greatly reduced at the point that coincides with the 
accumulation of SDS-resistant species (figure 3.5B, figure 3.6). Flies expressing intact 
pathogenic ataxin-3, which have SDS-resistant species present at day one after eclosion, perform 
consistently worse than control flies and HNHH-mutant counterparts.  
 We showed that disrupting the interaction between these two proteins, ataxin-3 and VCP, 
improves motility in flies. HNHH mutant expressing flies performed as well as control flies until 
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about three weeks of age, but those flies expressing intact pathogenic ataxin-3 were already 
slower at day seven. Furthermore, we showed that mutating the VBM decreases toxicity of 
pathogenic ataxin-3 when expressed in fly eyes. Substantial degeneration is seen with intact 
pathogenic ataxin-3 expression in the eyes, complete loss of ommatidial structure with 
accompanying aggregates. Mutation of the VBM to disrupt the interaction between ataxin-3 and 
VCP retains eye structure at four weeks and is more comparable to control eyes without 
pathogenic ataxin-3 expression. These findings were complemented with studies where we 
knocked down endogenous VCP in fly eyes in the presence of pathogenic ataxin-3 and found that 
decreasing levels of VCP was also able to reduce some of the toxicity that was observed when 
pathogenic ataxin-3 was expressed in the fly eyes alone. 
 Collectively, our results show that mutating the VBM of pathogenic ataxin-3 delays the 
aggregation of ataxin-3 into SDS-resistant aggregates in a Drosophila model of SCA3. This 
delay in aggregate accumulation coincides with a delay in toxicity in the flies. We observed with 
all Gal4 drivers, sqh-Gal4, elav-Gal4, and GMR-Gal4, that pathogenic ataxin-3 with mutated 
VBM was less toxic initially in flies, but did not alter ultimate fate of the flies.   
 An interesting finding arose from our studies when we induced pan-neuronal expression 
of ataxin-3 proteins after flies eclosed from the pupal case, that is, when we restricted expression 
to only during adulthood. We saw that these flies died at the same age as their counterparts in 
which the ataxin-3 proteins were expressed throughout development and adulthood (figure 3.5C, 
figure 3.9B). When intact pathogenic ataxin-3 is expressed during development with the elav-
Gal4 driver, flies already show accumulation of SDS-resistant ataxin-3 species at day one, 
whereas those flies in which pathogenic ataxin-3 expression is induced starting at day one 
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accumulation of ataxin-3 starts at day 10 of age (figure 3.5A and C, figure 3.9B). Similarily, in 
flies expressing HNHH mutated pathogenic ataxin-3 driven by the RU-486-inducible driver die 
at about the same age as those flies where protein expression is driven during development. 
Initially, this experiment was designed to assess when protein aggregation begins and when death 
ensues in SCA3 flies. The results of this experiment lead to the question of how flies are able to 
tolerate protein accumulation during development, since flies expressing intact pathogenic 
ataxin-3 throughout development and in adults show protein accumulation at day one (figure 
3.5A). Further experiments are necessary to look at differences in expression levels by the 
different drivers, and whether we observe death at the same time simply due to high expression 
levels caused by RU-486-inducible elav-Gal4 driver as opposed to the other non inducible elav-
Gal4 driver.  
 Non-pathogenic ataxin-3 itself has a propensity to aggregate. This is believed to happen 
through a two step process based on in vitro data with reconstituted systems using purified, 
recombinant proteins (Masino et al., 2004; Ellisdon et al., 2006; Masino et al., 2011). Ataxin-3 
that does not contain an expanded polyQ tract is thought to first dimerize through the catalytic 
Josephin Domain in the structured N-terminal; in a second less understood step the C-terminal 
tails of the proteins come together to create a ‘bead-on-a-string’ type structure and these further 
assemble into SDS-soluble protein aggregates (Ellisdon et al., 2006; Masino et al., 2011). This 
process is also thought to occur in the same two step manner when ataxin-3 contains an 
expanded polyQ region, although, in that instance highly stable, SDS-insoluble aggregates are 
formed, again in vitro (Ellisdon et al., 2006; Masino et al., 2011). Based on the data we presented 
here, we propose that VCP acts as a nucleating agent in initial ataxin-3 binding and fibrilization. 
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Ataxin-3 directly binds to VCP through its VBM domain. VCP functions as a hexameric 
complex and could potentially bind up to six ataxin-3 proteins (Boeddrich et al., 2006; Xia et al., 
2016). We propose that VCP, by binding to ataxin-3, increases the local concentration of the 
protein and also increases the likelihood of binding between ataxin-3 molecules and eventual 
formation into larger protein aggregates (figure 3.10). 
 In summary, we presented work that shows VCP involvement in protein aggregation in 
the polyQ disease, SCA3. This interaction may not only be limited to this protein interaction as 
there is work that points to VCP interacting with other polyQ disease related proteins (Fujita et 
al., 2013). Thus, the interaction between VCP and ataxin-3 can be applied to other polyQ 
diseases. One potential way to address the interaction between in VCP and pathogenic ataxin-3 
in the cell would be to create peptides which could compete with ataxin-3 for binding to VCP by 
mimicking the arginine-lysine rich RKRR sequence of the VBM of ataxin-3 (figure 4.1). This is 
what we examined next. 
$  
Figure 3.10 Model. 
Ataxin-3 directly binds to VCP by the VBM on its C-Terminal domain, VCP acts as a nucleating agent 
and increases the local concentration of ataxin-3 increasing the likelihood of interaction and 
aggregation. 
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CHAPTER 4: PROBING THE INTERACTION BETWEEN ATAXIN-3 AND VCP AS A 
POTENTIAL THERAPEUTIC TARGET  
4.1 Introduction 
 As stated earlier, there is currently no cure for SCA3. Some relief is available to patients 
through symptomatic therapies, unfortunately, all those affected succumb to this progressive 
disease (Costa Mdo and Paulson, 2012). Our goal was to study the interaction between ataxin-3 
and VCP and hope that this interaction could be exploited as a potential therapeutic target. Our 
results above showed that disrupting this interaction reduces the toxicity observed from 
pathogenic ataxin-3 in Drosophila. We presented evidence that disrupting the interaction 
between ataxin-3 and VCP delays the accumulation of SDS-resistant species in the fly and 
delayed toxicity: flies remained healthier for a longer period of time and performed better in 
physiological assays. Our collective results led us to propose a model in which VCP, through 
direct binding to ataxin-3, acts as a nucleation site for aggregation, bringing together in closer 
proximity pathogenic ataxin-3 proteins and increasing the likelihood of interaction and 
eventually fibrilization and protein aggregate accumulation (Figure 3.10). To date, no studies 
have shown that VCP is required for ataxin-3 function, except in ERAD (Wang et al., 2006; 
Zhong and Pittman, 2006) and that role for ataxin-3 is highly debatable. This led us to the idea of 
disrupting this interaction for SCA3 therapy. 
  We wanted to design an approach that could disrupt the interaction between these two 
proteins. We began by creating peptides that would potentially disrupt the interaction between 
ataxin-3 and VCP, by utilizing the RKRR region of ataxin-3. We created five decoy peptides that 
contained the VBM sequence RKRR from ataxin-3 with increasing amino acids from the 
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ataxin-3 backbone on either side of it, with a HIS6-tag for detection (figure 4.1). These peptides 
were transgenically expressed in flies. We created five new Drosophila lines, each one encoding 
a different peptide (Note: Decoy 2 has not yet been utilized in experiments). This was done using 
the PhiC31 site specific integrase, to insert the decoy peptides at the attP40 landing site, on 
chromosome 2 of the fly (Markstein et al., 2008). 
4.2 Materials and Methods  
Drosophila lines: Flies encoding decoys were generated by cloning the different decoy 
constructs into the pWalium10-moe vector (as described in Sutton et. al. 2017). Injections (Duke 
University Model System) were into y,w; attP40; +. 
Longevity assay: Conducted as previously described in chapter 3: flies were collected after 
eclosure and aged until death. Flies were switched to vials containing new food every two to 
three days.   
4. 3 Results and Discussion 
 We began by examining first whether these decoy peptides were toxic to the flies when 
expressed ubiquitously in all tissues (Figure 4.2). The reason for this initial approach was due to 
the fact that VCP binds to other proteins through their VBM including, HDR1 and E4B 
(Morreale et al., 2009). Thus, we wanted to make sure that the decoys were not toxic due to 
interrupting all VCP interactions. VCP and ataxin-3 are both ubiquitously expressed in human 
tissues. Expression of the decoys by themselves did not appear to be toxic, as the longevity of 
flies expressing the different decoys followed the longevity curve of the control flies for the most 
part (figure 4.2). The control flies in this experiment were host flies that were used to create our 
transgenic decoy flies (y,w; attp40; +), that also contained the ubiquitous, sqh-Gal4 driver but no 
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decoy. Flies ubiquitously expressing decoy one, three and four closely matched longevity of the 
control flies; we observed 50% death in these lines at around 50 days of age, whereas flies 
expressing decoy five had 50% death on day 31 (Figure 4.2, red line). Overall, flies expressing 
decoy five showed earlier death than the other decoys. Decoy five is the longest decoy; that is, it 
contains more of the ataxin-3 backbone than the other decoys (Figure 4.1). The earlier death that 
we observed with decoy five may be due to the possibility that this decoy mimics more closely 
the folding of the VBM and may be competing with VBM containing endogenous proteins better 
and disrupting important interactions, such as that of VCP with the ERAD ligases HRD1 and 
E4B (Morreale et al., 2009). It is also important to note that overall, the normal lifespan of  the 
isogenic, host background flies used to create the decoys is shorter compared to the control lines 
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Figure 4.1: Ataxin-3 sequence, decoy design.  
Top, shown is amino acid sequence of ataxin-3, with expanded polyQ, VBM sequence shown in red. 
Chart, sequences of five decoy peptides. HIS6-tag in green. Note: decoy 2 has not yet been utilized in 
experiments.
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used in experiments described in Chapter 3, which lived up to ~90 days (figure 3.4, 3.5). This is 
due to the difference in genetic backgrounds used to make the decoy flies, in which constructs 
were specifically inserted at a specific site, attP40, on chromosome two as compared to 
chromosome three site attP2 for the pathogenic ataxin-3 encoding transgenic flies. This point 
highlights the need to always control for the proper genetic background when examining fly 
longevity. 
 We were ultimately interested in whether these decoys could reduce or prevent the 
toxicity we observe from intact pathogenic ataxin-3. In other words, could these decoys disrupt 
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Figure 4.2; Ubiquitous expression of decoys. 
Longevity curves for flies expressing respective decoys in all tissues of the fly with the ubiquitous driver, 
sqh-Gal4. Approximately 25 flies per vial were collected shortly following eclosion and aged. Death was 
monitored on a daily basis until all flies were dead. Control flies were flies with the same isogenic 
background originally used to create decoy containing transgenic fly line, with the sqh-Gal4 driver. Flies 
were transferred to vials containing new food every two to three days. 
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the interaction between ataxin-3 and VCP like mutating the VBM of ataxin-3 did, to delay the 
accumulation of aggregates in the fly? To better assess how toxicity of pathogenic ataxin-3 is 
affected by expression of decoy peptides in the whole fly, we first expressed pathogenic ataxin-3 
on the same genetic host background as flies encoding the decoys. Using the ubiquitous, sqh-
Gal4 driver to express pathogenic ataxin-3 in the whole fly, we observed that ataxin-3 on this 
genetic background was extremely toxic and flies died as pharate adults: no flies eclosed from 
the pupal case (figure 4.3, red arrow). In comparison, when we expressed any of the decoys 
alongside ataxin-3 in the whole fly, toxicity was reduced and flies eclosed from the pupal case. 
We observed a similar trend as the above experiment (Figure 4.2): flies expressing decoy one 
and pathogenic ataxin-3 lived longer than flies expressing the other decoys with pathogenic 
ataxin-3 (Figure 4.3, green line), and those flies expressing decoy five exhibited the shortest 
lifespan (Figure 4.3, red line). Overall, however, these flies are still not outliving their 
counterparts expressing pathogenic ataxin-3 at the attP2 site (figure 4.3, blue line). Future work 
needs to confirm that the decoys work as intended. It needs to be confirmed that they are specific 
for the ataxin-3-VCP interaction and are not disrupting interaction between VCP and other 
partners such as HRD1 and E4B.  
 As we showed in Chapter 3, expression of pathogenic ataxin-3 in the nervous system is 
less toxic to the fly than ubiquitous expression; flies expressing pathogenic ataxin-3 pan-
neuronally all eclose from the pupal case and live longer than flies expressing pathogenic 
ataxin-3 ubiquitously (figure 3.4A and figure 3.5B). This gave us a longer timeline to examine 
decoy expression and its outcomes in flies. It is also a good model to examine the effects of 
pathogenic ataxin-3 and the decoys in the nervous system specifically. Thus, we expressed the 
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different decoys alongside pathogenic ataxin-3 with the pan-neuronal driver, elav-Gal4 (figure 
4.4). We did not observe a difference in lifespan between flies expressing any decoy along side 
pathogenic ataxin-3 and flies in which pathogenic ataxin-3 was expressed alone pan-neuronally 
(figure 4.4, blue line). Leading us to the conclusion that pan-neuronal expression of decoy 
peptides does not reduce toxicity caused by pathogenic ataxin-3. 
 A shortcoming of these studies is that the line that was used to create the transgenic decoy 
flies is not as healthy as the fly line used to create the pathogenic ataxin-3 fly line. The decoys 
were inserted into the second chromosome, at the attP40 landing site, whereas the ataxin-3 
transgene was inserted at the attP2 site on the third chromosome. We noticed during our studies 
that the fly line encoding the attP40 site was not as healthy as the other fly lines we used in the 
lab. This has made it difficult to easily examine whether the decoy peptides are improving the 
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Figure 4.3; Ubiquitous expression of decoys with pathogenic ataxin-3 in the fly.  
Longevity of flies when expression of pathogenic ataxin-3 and decoy was in all tissues driven by the 
ubiquitous driver, sqh-Gal4. Longevity assay conducted in same manner as stated in Figure 4.2. 
Arrow denotes time of death for flies expressing pathogenic ataxin-3 on the attP40 genetic background.
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phenotype that we see when pathogenic ataxin-3 is expressed, as the lifespan of flies is greatly 
shortened.  
 These experiments are still informative, however, and at the very least indicate that the 
decoys might not be as useful as originally intended to suppress toxicity from ataxin-3 in the fly. 
Further biochemical and physiological assays are necessary to understand their ability to engage 
VCP, to disrupt ataxin-3 interaction with VCP (and potentially other proteins that bind VCP 
through a similar region as ataxin-3’s), and to reduce the aggregation of ataxin-3 in vivo. It will 
be beneficial to test these decoys in cells, by performing immuno-precipitation experiments to 
see how well each decoy binds to VCP, co-immunoprecipitation experiments to study how 
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Figure 4.4: Pan-neuronal expression of decoys with pathogenic ataxin-3 in the fly.  
Longevity of flies expressing respective decoy and pathogenic ataxin-3 in the nervous system. 
Expression of transgenes driven by pan-neuronal driver, elav-Gal4. Control flies were flies with the 
same isogenic background as those encoding decoys, with elav-Gal4. Longevity assessed in same 
manner as in figures above, Figure 4.2 and 4.3.
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expression of the decoys affects ataxin-3 binding to VCP and then further experiments to 
examine the effects of these decoys on protein aggregation in cells. In preliminary data, decoys 3 
and 5 bind fly and human VCP very well, based on biochemical studies (Todi. S, Sutton. J, data 
not shown). The goal of transgenically expressing the decoy peptides was to obtain a general 
idea of whether or not we are able to disrupt the interaction between pathogenic ataxin-3 and 
VCP to decrease toxicity similarly to how we do by mutating the VBM. Future studies of these 
decoys should include orally feeding the decoys to Drosophila, although, based on my data so far 
this might not be a successful approach overall. 
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CHAPTER 5: CONCLUSIONS 
 The UPP is a vital pathway in the cell. It is necessary to rid the cell of mutant, misfolded 
or aberrant proteins in order to keep the cell functioning properly. Ubiquitination and 
deubiquitination play an important role in making sure this process happens in a controlled 
manner, by tagging proteins for degradation by ubiquitination, or saving them by removing their 
ubiquitin tag. When perturbations in this system arise, they can result in various deleterious 
diseases as highlighted in chapter one of this thesis. The overall goal of the research described in 
this thesis was to tackle two DUBs, one critical for normal physiological function (USP5), and 
the other directly linked to disease (ataxin-3). 
 I began my journey by investigating USP5. The findings in chapter two examined 
physiological function of USP5 in vivo in the fly. Although earlier reports proposed that the main 
function of USP5 was that of a mono-Ub recycler, our results showed that knockdown of USP5 
in the fly, which was lethal during development, resulted in the accumulation of poly-Ub chains 
but not the depletion of mono-Ub. This led us to propose that USP5 was acting to hydrolyze 
ubiquitin chains to prevent their accumulation and hindrance of protein degradation in the cell. 
Reports published following ours also indicated the importance of USP5 handling poly-Ub 
chains to keep protein degradation operational. One group showed that USP5 mutant flies had 
abnormal neuromuscular junction morphology of the post synaptic end due to impairment of 
protein degradation (Wang et al., 2017). Other work highlighted the importance of USP5 as a 
direct DUB for specific proteins, supporting my in vitro results that USP5 can and does act on 
specific proteins (Garcia-Caballero et al., 2014). 
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 As mentioned in chapter two, a paper by Garcia-Caballero et. al. showed that USP5 
interacted with and deubiquinated the T-type calcium channel Cav3.2 in inflammatory and 
neuropathic pain models in rodents (Garcia-Caballero et al., 2014). The authors showed that 
USP5 could modulate the levels of this channel by deubiquitinating it and thus rescuing it from 
proteasomal degradation, increasing its overall cellular levels. We also showed that USP5 could 
have substrates other than unanchored poly-Ub chains. In a series of  in vitro deubiquitinating 
reactions with recombinant proteins, we showed that USP5 could deubiquitinate CHIP, but it did 
not deubiquitinate Hsp70. These results raise the distinct possibility that USP5 has other specific 
substrates in the cell. This would be an interesting route to explore, since even though there are 
some overlapping roles between different DUBs, nothing seems able to compensate for loss of 
function of USP5, as its mutation or knockdown results in death during fly development.  
 My in vitro  results with USP5 and CHIP uncover a potential link that could connect 
USP5 and ataxin-3. Studies have shown that wild type ataxin-3 can deubiquitinate CHIP; 
pathogenic ataxin-3 is unable to perform this function as well, and leads to decreased CHIP 
proteins levels in a SCA3 mouse model (Scaglione et al., 2011). CHIP has been shown over and 
over again to play an important role in suppressing polyQ related protein aggregation (Miller et 
al., 2005; Williams and Paulson, 2008). Whether CHIP is a substrate of USP5 in vivo remains to 
be studied, but it would be interesting to investigate whether USP5 deubiquitination of CHIP 
leads to an increase in protein levels as a protective mechanism in polyQ disease, or if it 
additionally decreases its levels and causes more toxicity. 
 Another interesting question to explore in terms of pathogenic ataxin-3 and aggregation 
in Drosophila is whether it is a reversible process, or if it is a point of no return. Is there a point 
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at which the cell could remove protein aggregates, when there is no additional burden by 
expression of pathogenic ataxin-3? Can neurons handle an amount of aggregates and survive 
with them, or once accumulation starts does it ever stop? I propose that stopping expression of 
the disease protein could reduce toxicity and prolong the lifespan of the SCA3 flies. This type of 
experiment would also be able to show us whether aggregates are cleared from the cell: do the 
smears on western blots decrease with time, or will they stop accumulating and remain at the 
same level? With the tools available to us, we would be able to express this protein in the whole 
fly and in a tissue specific manner. We would also be able to control when to start expression of 
ataxin-3, and as a natural extension of these tools we would also be able to utilize them to stop 
the expression of ataxin-3 in the fly. To study how stopping the expression of pathogenic 
ataxin-3 may affect toxicity in flies, I would propose to once again utilize the RU-486-inducible 
drivers. We would cross and raise flies on regular media without RU-486. Once flies eclose from 
the pupal case, they would be moved to RU468-containing food to activate expression of 
pathogenic ataxin-3. These flies would be aged on RU-486 food and flies collected at different 
time points to monitor expression of ataxin-3 by western blot of whole fly lysates. From our 
previous experiment with RU-486 inducible expression of pathogenic ataxin-3, we saw that 
accumulation of aggregates starts around day 10 of the fly life; we could use this as a starting 
point to stop ataxin-3 expression by moving flies from RU-486 containing food back to regular 
media. We would also monitor how long it takes for ataxin-3 expression and aggregation to be 
eliminated by collecting flies for lysates at multiple times after they are moved to regular fly 
media,. For flies expressing HNHH mutant ataxin-3, following the same logic as above and 
stopping ataxin-3 expression at a point when we first began to observe protein aggregation, a 
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good starting point to move the flies to food lacking RU-486 would be around day 21.We would 
also conduct longevity studies to see if the lifespan of flies is prolonged after ataxin-3 expression 
is stopped. This experiment has the potential to answer various questions regarding ataxin-3 
aggregation and its toxicity in vivo, including the temporal relation between the two; it would 
also give more clues into whether removing a mutant protein from the organism would have a 
positive outcome and further decrease toxicity in the fly. This point could be explored for other 
polyQ diseases and a potential therapeutic strategy.  
 In conclusion, our studies provided new insights on the involvement of DUBs in the 
maintenance of ubiquitin homeostasis and in disease. Starting from a cellular function 
perspective, we examined the role of  USP5 function in vivo in Drosophila, in contrary to earlier 
notions, we found that USP5 functioned to hydrolyze unanchored poly-Ub chains and not as a 
recycler of mono-Ub. Recent publications about USP5 support the idea that USP5 plays a role in 
maintaining normal function of the proteasome by acting on unanchored poly-Ub chains to 
prevent them from blocking proteasome substrates destined for degradation (Ling et al., 2017; 
Wang et al., 2017). Perhaps most intriguing of all, we showed that this enzyme could 
deubiquitinate a substrate in an in vitro reaction, substrate specificity would most likely be able 
to explain the developmental death observed when USP5 is knocked down in the fly. From a 
disease standpoint, we studied the ataxin-3 and VCP interaction role in SCA3 pathogensis. Our 
work built on previously published work that discovered this interaction and show that VCP has 
the ability to modulate pathogenic ataxin-3 toxicity in an in vivo disease model. We showed that 
disrupting the interaction between these two proteins results in the delay of protein aggregation 
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and toxicity. This interaction offers a potentially promising therapeutic target to further 
investigate for SCA3 treatment.  
 DUBs serve an important role in the cell, as highlighted in the studies above. There are 
over 90 DUBs in humans and we are just skimming the surface in terms of understanding their 
roles, functions and substrates in the cells. This field offers many exciting possibilities that need 
to be further investigated. 
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 Protein quality control (PQC) is indispensable for normal cellular functions, ensuring 
proteins are properly folded and removing those proteins that are functioning aberrantly. 
Perturbations in PQC can lead to various malignancies, neurodegeneration and neurological 
diseases. The Ubiquitin-Proteasome Pathway (UPP) is one important pathway in PQC, it relies 
on ubiquitination-dependent post-translational modification to selectively degrade misfolded or 
short-lived protein. Ubiquitination is reversed by the action of proteases known as 
deubiquitinating enzymes (DUBs). By hydrolyzing ubiquitin linkages, DUBs are responsible for 
cleaving and activating newly produced ubiquitin molecules, editing poly-Ub chains, removing 
ubiquitin from a substrate protein and recycling mono-Ub. Here, I investigated two proteins 
critically involved in the UPP: one that is important for normal cellular function (USP5), and 
another whose mutations cause neurodegeneration (ataxin-3).  
 Ubiquitin Specific Protease 5 (USP5) is a member of the USP class of DUBs. Based on 
structural and in vitro results, it was long thought to function as a recycler of mono-Ub in the 
cell, by hydrolyzing unanchored poly-Ub chains. We studied the function of USP5 in vivo in 
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Drosophila melanogaster. Knockdown of DmUSP5 in the whole fly results in death during 
developmental stages and in an increase in poly-Ub chains, but does not result in a depletion of 
mono-Ub in the fly, contrary to long-held opinion. Based on our data, lethality from USP5 
knockdown is not due to depletion of mono-Ub, but likely resulted due to accumulation of 
unanchored poly-Ub chains and disruption of proteasomal degradation. Our results also suggest 
that USP5 has specific substrates. 
 The other DUB investigated, ataxin-3, is the disease causing protein in the age-related, 
poly-glutamine (polyQ) dependent disease Spinocerebellar Ataxia Type-3 (SCA3). Through its 
different interacting partners, ataxin-3 is involved in protein quality control pathways. One such 
protein is the AAA ATPase Valosin Containing Protein (VCP). Ataxin-3 interacts directly with 
VCP through a VCP Binding Motif (VBM). Through biochemistry, Drosophila genetics and 
physiological assays, we showed that pathogenic ataxin-3 with a  mutated VBM is markedly less 
toxic than its intact pathogenic counterpart. Mutating the VBM of ataxin-3 caused a delay in the 
aggregation of ataxin-3 in vivo, in various tissues tested. We propose that VCP acts as a 
nucleation center to increase local concentrations of ataxin-3 proteins and increase their 
likelihood of interacting and fibrilization. Our work suggest this interaction as a potential 
therapeutic target for SCA3.  
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